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Summary
On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) formulated for use in
adults and adolescents was licensed in the United States for persons aged 11–64 years (ADACEL®, manufactured by sanofi
pasteur, Toronto, Ontario, Canada). Prelicensure studies demonstrated safety and efficacy, inferred through immunogenicity,
against tetanus, diphtheria, and pertussis when Tdap was administered as a single booster dose to adults. To reduce pertussis
morbidity among adults and maintain the standard of care for tetanus and diphtheria prevention and to reduce the transmission
of pertussis to infants and in health-care settings, the Advisory Committee on Immunization Practices (ACIP) recommends that:
1) adults aged 19–64 years should receive a single dose of Tdap to replace tetanus and diphtheria toxoids vaccine (Td) for booster
immunization against tetanus, diphtheria, and pertussis if they received their last dose of Td >10 years earlier and they have not
previously received Tdap; 2) intervals shorter than 10 years since the last Td may be used for booster protection against pertussis;
3) adults who have or who anticipate having close contact with an infant aged <12 months (e.g., parents, grandparents aged <65
years, child-care providers, and health-care personnel) should receive a single dose of Tdap to reduce the risk for transmitting
pertussis. An interval as short as 2 years from the last Td is suggested; shorter intervals can be used. When possible, women should
receive Tdap before becoming pregnant. Women who have not previously received Tdap should receive a dose of Tdap in the
immediate postpartum period; 4) health-care personnel who work in hospitals or ambulatory care settings and have direct patient
contact should receive a single dose of Tdap as soon as feasible if they have not previously received Tdap. An interval as short as 2
years from the last dose of Td is recommended; shorter intervals may be used. These recommendations for use of Tdap in health-
care personnel are supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC). This statement 1)
reviews pertussis, tetanus and diphtheria vaccination policy in the United States; 2) describes the clinical features and epidemiol-
ogy of pertussis among adults; 3) summarizes the immunogenicity, efficacy, and safety data of Tdap; and 4) presents recommen-
dations for the use of Tdap among adults aged 19–64 years.
Introduction
Pertussis is an acute, infectious cough illness that remains
endemic in the United States despite longstanding routine
childhood pertussis vaccination (1). Immunity to pertussis
wanes approximately 5–10 years after completion of child-
hood vaccination, leaving adolescents and adults susceptible
to pertussis (2–7). Since the 1980s, the number of reported
pertussis cases has steadily increased, especially among ado-
lescents and adults (Figure). In 2005, a total of 25,616 cases
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of pertussis were reported in the United States (8). Among
the reportable bacterial vaccine-preventable diseases in the
United States for which universal childhood vaccination has
been recommended, pertussis is the least well controlled (9,10).
In 2005, a tetanus toxoid, reduced diphtheria toxoid and
acellular pertussis vaccine, adsorbed (Tdap) product formu-
lated for use in adults and adolescents was licensed in the
United States for persons aged 11–64 years (ADACEL®, sanofi
pasteur, Toronto, Ontario, Canada) (11). The Advisory Com-
mittee on Immunization Practices (ACIP) reviewed evidence
and considered the use of Tdap among adults in public meet-
ings during June 2005–February 2006. On October 26, 2005,
ACIP voted to recommend routine use of Tdap among adults
aged 19–64 years. For adult contacts of infants, ACIP recom-
mended Tdap at an interval as short as 2 years since the pre-
vious Td. On February 22, 2006, ACIP recommended Tdap
for health-care personnel (HCP), also at an interval as short
as 2 years since the last Td. This report summarizes the ratio-
nale and recommendations for use of Tdap among adults in
the United States. Recommendations for the use of Tdap
among adolescents are discussed elsewhere (12).
Pertussis Vaccination Policy
In the United States during 1934–1943, an annual average
of 200,752 pertussis cases and 4,034 pertussis-related deaths
were reported (13,14; Sirotkin B, CDC, personal communica-
tion, 2006). Although whole cell pertussis vaccines became
available in the 1920s (15), they were not routinely recom-
mended for children until the 1940s after they were combined
with diphtheria and tetanus toxoids (DTP) (16,17). The num-
ber of reported pertussis cases declined dramatically following
introduction of universal childhood pertussis vaccination (1).
Pediatric acellular pertussis vaccines (i.e., diphtheria and
tetanus toxoids and acellular pertussis antigens [DTaP]), less
reactogenic than the earlier whole-cell vaccines, were first licensed
for use in children in 1991 (18,19). ACIP recommended that
pediatric DTaP replace all pediatric DTP doses in 1997 (1).
In 2005, two Tdap products were licensed for use in single
doses in the United States (11,20). BOOSTRIX®
(GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed
only for adolescents aged 10–18 years. ADACEL® (sanofi
pasteur, Toronto, Ontario, Canada) is licensed for adolescents
and adults aged 11–64 years. ACIP has recommended that
adolescents aged 11–18 years receive a single dose of either
Tdap product instead of adult tetanus and diphtheria toxoids
(Td) for booster immunization against tetanus, diphtheria,
and pertussis if they have completed the recommended child-
hood DTP or DTaP vaccination series and have not received
Td or Tdap; age 11–12 years is the preferred age for the ado-
lescent Tdap dose (12).
One of the Tdap vaccines, ADACEL® (sanofi pasteur) is
licensed for use in adults and adolescents (11). All references
to Tdap in this report refer to the sanofi pasteur product un-
less otherwise indicated. Tdap is licensed for 1-dose adminis-
tration (i.e., not for subsequent decennial booster doses or
subsequent wound prophylaxis). Prelicensure studies on the
safety or efficacy of subsequent doses were not conducted.
No vaccine containing acellular pertussis antigens alone (i.e.,
without tetanus and diphtheria toxoids) is licensed in the
United States. Acellular pertussis vaccines formulated with
tetanus and diphtheria toxoids have been available for use
among adolescents and adults in other countries, including
Canada, Australia and an increasing number of European
countries (e.g., France, Austria and Germany) (21–27).
The efficacy against pertussis of an adolescent and adult
acellular pertussis (ap) vaccine with the same pertussis anti-
gens as those included in BOOSTRIX® (without tetanus and
diphtheria toxoids) was evaluated among 2,781 adolescents
and adults in a prospective, randomized trial in the United
States (28). Persons aged 15–64 years were randomized to
receive one dose of ap vaccine or hepatitis A vaccine (Havrix®,
GlaxoSmithKline Biologicals, Rixensart, Belgium). The primary
outcome measure was confirmed pertussis, defined as a cough
illness lasting >5 days with laboratory evidence of Bordetella
pertussis infection by culture, polymerase chain reaction (PCR),
or paired serologic testing results (acute and convalescent). Nine
persons in the hepatitis A vaccine control group and one per-
son in the ap vaccine group had confirmed pertussis during the
study period; vaccine efficacy against confirmed pertussis was
92% (95% confidence interval [CI] = 32%–99%) (28). Re-
sults of this study were not considered in evaluation of Tdap
for licensure in the United States.
FIGURE. Number of reported pertussis cases, by year —
United States, 1922–2005
* Introduction of universal pediatric diphtheria and tetanus toxoids and
whole-cell pertussis vaccine.
SOURCE: 1950–2005, CDC, National Notifiable Diseases Surveillance
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Objectives of Adult Pertussis
Vaccination Policy
The availability of Tdap for adults offers an opportunity to
reduce the burden of pertussis in the United States. The pri-
mary objective of replacing a dose of Td with Tdap is to pro-
tect the vaccinated adult against pertussis. The secondary
objective of adult Tdap vaccination is to reduce the reservoir
of pertussis in the population at large, and thereby poten-
tially 1) decrease exposure of persons at increased risk for com-
plicated infection (e.g., infants), and 2) reduce the cost and




Pertussis is an acute respiratory infection caused by
B. pertussis, a fastidious gram-negative coccobacillus. The or-
ganism elaborates toxins that damage respiratory epithelial
tissue and have systemic effects, including promotion of lym-
phocytosis (29). Other species of bordetellae, including
B. parapertussis and less commonly B. bronchiseptica or
B. holmseii, are associated with cough illness; the clinical pre-
sentation of B. parapertussis can be similar to that of classic
pertussis. Illness caused by species of bordetellae other than
B. pertussis is not preventable by available vaccines (30).
Pertussis is transmitted from person to person through large
respiratory droplets generated by coughing or sneezing. The
usual incubation period for pertussis is 7–10 days (range: 5–
21 days) (16,31,32). Patients with pertussis are most infec-
tious during the catarrhal and early paroxysmal phases of illness
and can remain infectious for >6 weeks (16,31,32). The in-
fectious period is shorter, usually <21 days, among older chil-
dren and adults with previous vaccination or infection. Patients
with pertussis are highly infectious; attack rates among ex-
posed, nonimmune household contacts are as high as 80%–
90% (16,32,33).
Factors that affect the clinical expression of pertussis in-
clude age, residual immunity from previous vaccination or
infection, and use of antibiotics early in the course of the
illness before the cough onset (32). Antibiotic treatment gen-
erally does not modify the course of the illness after the onset
of cough but is recommended to prevent transmission of the
infection (34–39). For this reason, vaccination is the most
effective strategy for preventing the morbidity of pertussis.
Detailed recommendations on the indications and schedules
for antimicrobials are published separately (34).
Clinical Features and Morbidity Among
Adults with Pertussis
B. pertussis infection among adults covers a spectrum from
mild cough illness to classic pertussis; infection also can be
asymptomatic in adults with some level of immunity. When
the presentation of pertussis is not classic, the cough illness
can be clinically indistinguishable from other respiratory ill-
nesses. Classic pertussis is characterized by three phases of
illness: catarrhal, paroxysmal, and convalescent (16,32). Dur-
ing the catarrhal phase, generally lasting 1–2 weeks, patients
experience coryza and intermittent cough; high fever is un-
common. The paroxysmal phase lasts 4–6 weeks and is char-
acterized by spasmodic cough, posttussive vomiting, and
inspiratory whoop (16). Adults with pertussis might experi-
ence a protracted cough illness with complications that can
require hospitalization. Symptoms slowly improve during the
convalescent phase, which usually lasts 2–6 weeks, but can
last for months (Table 1) (32).
Prolonged cough is a common feature of pertussis. In stud-
ies of adults with pertussis, the majority coughed for >3 weeks
and some coughed for many months (Table 1). Because of
TABLE 1. Cough duration reported in adults with pertussis — selected countries or regions, 2005
Quebec Sweden Germany United Kingdom Australia
Cough duration (n = 384*) (n = 155†) (n = 79§) (n = 77¶) (n = 63**)
Cough >3 weeks 97% —†† 80% 100% —
Cough >6 weeks — — — 47% —
Cough >9 weeks 55% — — — —
Median duration (weeks) — 8 7 — 8.6
Mean duration (weeks) 12 — 7.7 — —
Range, low (weeks) — 2 — 3 0.5
Range, high (weeks) — 26 32 32 21
* Source: De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174–9.
† Source: Trollfors B, Rabo E. Whooping cough in adults. Br Med J 1981;283:696–7.
§ Source: Postels-Multani S, Schmitt HJ, Wirsing von Konig CH, Bock HL, Bogaerts H. Symptoms and complications of pertussis in adults. Infection
1995;23:139–42.
¶ Source: MacLean DW. Adults with pertussis. J R Coll Gen Pract 1982;2:298–300.
** Source: Thomas PF, McIntyre PB, Jalaludin BB. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 2000;173:74–6.
†† Not available.
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the prolonged illness, some adults undergo extensive medical
evaluations by providers in search of a diagnosis, if pertussis
is not considered. Adults with pertussis often make repeated
visits for medical care. Of 2,472 Massachusetts adults with
pertussis during 1988–2003, a total of 31% had one, 31%
had two, 35% had three or more medical visits during their
illness; data were not available for 3% (Massachusetts De-
partment of Public Health, unpublished data, 2005). Simi-
larly, adults in Australia with pertussis reported a mean of 3.7
medical visits for their illness, and adults in Quebec visited
medical providers a mean of 2.5 times (40,41). Adults with
pertussis miss work: in Massachusetts, 78% of 158 employed
adults with pertussis missed work for a mean of 9.8 days
(range: 0.1–180 days); in Quebec, 67% missed work for a
mean of 7 days; in Sweden, 65% missed work and 16% were
unable to work for more than 1 month; in Australia, 71%
missed work for a mean of 10 days (range: 0–93 days) and
10% of working adults missed more than 1 month (40–43).
Adults with pertussis can have complications and might
require hospitalization. Pneumonia has been reported in up
to 5% and rib fracture from paroxysmal coughing in up to
4% (Table 2); up to 3% were hospitalized (12% in older
adults). Loss of consciousness (commonly “cough syncope”)
has been reported  in up to 3% and 6% of adults with pertus-
sis (41,42). Urinary incontinence was commonly reported
among women in studies that inquired about this feature
(41,42). Anecdotal reports from the literature describe other
complications associated with pertussis in adults. In addition
to rib fracture, cough syncope, and urinary incontinence, com-
plications arising from high pressure generated during cough-
ing attacks include pneumothorax (43), aspiration, inguinal
hernia (44), herniated lumbar disc (45), subconjunctival hem-
orrhage (44), and one-sided hearing loss (43). One patient
was reported to have carotid dissection (46). In addition to
pneumonia, other respiratory tract complications include
sinusitis (41), otitis media (41,47), and hemoptysis (48). Neu-
rologic and other complications attributed to pertussis in adults
also have been described, such as pertussis encephalopathy (i.e.,
seizures triggered by only minor coughing episodes) (49), mi-
graine exacerbation (50), loss of concentration/memory (43),
sweating attacks (41), angina (43), and severe weight loss (41).
Whether adults with co-morbid conditions are at higher
risk for having pertussis or of suffering its complications is
unknown. Adults with cardiac or pulmonary disease might
be at risk for poor outcomes from severe coughing paroxysms
or cough syncope (41,51). Two case reports of pertussis in
human immunodeficiency virus (HIV)-infected adults (one
patient with acquired immunodeficiency syndrome [AIDS])
TABLE 2. Clinical characteristics and complications in adults with pertussis
Proportion of adults with clinical feature
U.S. excluding U.S. excluding
Massachusetts Massachusetts Massachusetts Massachusetts Sweden Quebec Australia
Aged >18 yrs Aged >18 yrs Aged 19–64 yrs Aged >65 yrs Aged >20 yrs Aged >18 yrs Aged >18 yrs
2001–2003 1998–2000 1996–2004 1996–2004 1976–1978 1998 1997–1978
Feature (n = 936*) (n = 203*) (n = 18,243†)§ (n = 984†)§ (n = 155¶) (n = 384**) (n = 73††)
Paroxysmal cough 86% 84% 89% 86% —§§ 99% 82%
Difficulty sleeping — 84% — — — — 84%
Difficulty breathing — 86% — — — — —
Apnea 44% — 32% 32% — 85%  —
Posttussive vomiting 47% 54% 45% 27% 50% 61% 62%
Weight loss — 33% — — — — 33%
Whoop 41% — 37% 33% 82% 70% 45%
Urinary incontinence — 28%  — — — (34% women  —
aged >50 yrs)
Pneumonia 2% 5% 3%¶¶ 8%¶¶ 0.6% 5% 5%
Rib fracture — 4%  —  — 1% (4% in  —
women)
Seizure 0.3% — 0.6% 0.2% 0 0 0
Loss of consciousness — 6%  —  — 0 3% 0
Hospitalization 3% — 3% 12% 2% 2% 0
(6% aged
 >50 yrs)
* Source: Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004;39:1572–80.
† Source: CDC. National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System, 1996–2004. Atlanta, GA: US
Department of Health and Human Serivces, CDC, 2005.
§ For each factor, the percentage was calculated for cases in which information was available. The percentage of total cases for which data were
unavailable is as follows. For adults aged 19–64 years: paroxysmal cough (13%), vomiting (14%), whoop (17%), apnea (17%), pneumonia (23%),
hospitalization (16%), and seizure (16%); for adults aged >65 years: paroxysmal cough (15%), vomiting (17%), whoop (19%), apnea (19%), pneumo-
nia (25%), hospitalization (18%), and seizure (18%).
¶ Source: Trollfors B, Rabo E. Whooping cough in adults. Br Med J 1981;283:696–7.
** Source: De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174–9.
†† Source: Thomas PF, McIntyre PB, Jalaludin BB. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 2000;173:74–6.
§§ Not available.
¶¶ Radiographically confirmed.
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described prolonged cough illnesses and dyspnea in these pa-
tients, but no complications (52,53).
During 1990–2004, five pertussis-associated deaths among
U.S. adults were reported to CDC. The patients were aged
49–82 years and all had serious underlying medical condi-
tions (e.g., severe diabetes, severe multiple sclerosis with
asthma, multiple myeloma on immunosuppressive therapy,
myelofibrosis, and chronic obstructive pulmonary disease)
(54,55; CDC, unpublished data, 2005). In an outbreak of
pertussis among older women in a religious institution in The
Netherlands, four of 75 residents were reported to have suf-
fered pertussis-associated deaths. On the basis of clinical as-
sessments, three of the four deaths were attributed to
intracranial hemorrhage during pertussis cough illnesses that
had lasted >100 days (56).
Infant Pertussis and Transmission
to Infants
Infants aged <12 months are more likely to suffer from per-
tussis and pertussis-related deaths than older age groups, ac-
counting for approximately 19% of nationally reported
pertussis cases and 92% of the pertussis deaths in the United
States during 2000–2004. An average of 2,435 cases of per-
tussis were reported annually among infants aged <12 months,
of whom 43% were aged <2 months (CDC, unpublished data,
2005). Among infants aged <12 months reported with per-
tussis for whom information was available, 63% were hospi-
talized and 13% had radiographically confirmed pneumonia
(Table 3).
Rates of hospitalization and complications increase with
decreasing age. Young infants, who can present with symp-
toms of apnea and bradycardia without cough, are at highest
risk for death from pertussis (55). Of the 100 deaths from
pertussis during 2000–2004, a total of 76 occurred among
infants aged 0–1 month at onset of illness, 14 among infants
aged 2–3 months, and two among infants aged 4–11 months.
The case-fatality ratio among infants aged <2 months was
1.8%. A study of pertussis deaths in the 1990s suggests that
Hispanic infants and infants born at gestational age <37 weeks
comprise a larger proportion of pertussis deaths than would
be expected on the basis of population estimates (54). Two to
3 doses of pediatric DTaP (recommended at ages 2, 4, and 6
months) provide protection against severe pertussis (55,57).
Although the source of pertussis in infants often is unknown,
adult close-contacts are an important source when a source is
identified. In a study of infants aged <12 months with per-
tussis in four states during 1999–2002, parents were asked
about cough illness in persons who had contact with the in-
fant (58). In 24% of cases, a cough illness in the mother,
father, or grandparent was reported (Table 4).
Pertussis Diagnosis
Pertussis diagnosis is complicated by limitations of diag-
nostic tests for pertussis. Certain factors affect the sensitivity,
specificity, and interpretation of these tests, including the stage
of the disease, antimicrobial administration, previous vacci-
nation, the quality of technique used to collect the specimen,
transport conditions to the testing laboratory, experience of
the laboratory, contamination of the sample, and use of
nonstandardized tests (59,60). In addition, tests and speci-
men collection materials might not be readily available to
practicing clinicians.
Isolation of B. pertussis by culture is 100% specific; how-
ever, sensitivity of culture varies because fastidious growth
requirements make it difficult to transport and isolate the
organism. Although the sensitivity of culture can reach 80%–
90% under optimal conditions, in practice, sensitivity typi-
cally ranges from 30% to 60% (61). The yield of B. pertussis
from culture declines in specimens taken after 2 or more weeks
of cough illness, after antimicrobial treatment, or after previ-
ous pertussis vaccination (62). Three weeks after onset of
cough, culture is only 1%–3% sensitive (63). Although
B. pertussis can be isolated in culture as early as 72 hours after
TABLE 3. Hospitalizations and complications among infants








* Source: CDC. National Notifiable Diseases Surveillance System and
Supplemental Pertussis Surveillance System, 2000–2004. Atlanta, GA:
US Department of Health and Human Services, CDC, 2005.
†Percentages are based on total number with information. For 20% of
infants with cases, no information was available on hospitalization,
seizure, or apnea; for 30%, no information was available on pneumonia.
§Radiographically confirmed.
TABLE 4.  Relation and age of reported source of pertussis
among infants aged <12 months, 1999–2002*








* Source: Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis:
who was the source? Pediatr Infect Dis J 2004;23:985–9.
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plating, 1–2 weeks are required before a culture result can
definitively be called negative (64). Culture to isolate B. per-
tussis is essential for antimicrobial susceptibility testing, mo-
lecular subtyping, and validation of the results of other
laboratory assays.
Direct fluorescent antibody (DFA) tests provide results in
hours, but are generally less sensitive (sensitivity: 10%–50%)
than culture. With use of monoclonal reagents, the specific-
ity of DFA should be >90%; however, the interpretation of
the test is subjective, and misinterpretation by an inexperi-
enced microbiologist can result in lower specificity (65). Be-
cause of the limitations of DFA testing, CDC does not
recommend its use.
Because of increased sensitivity and shorter turn-around-
time, DNA amplification (e.g., PCR) is being used more fre-
quently to detect B. pertussis. When symptoms of classic
pertussis are present (e.g., 2 weeks of paroxysmal cough), PCR
typically is 2–3 times more likely than culture to detect
B. pertussis in a positive sample (59,66,67). The definitive
classification of a PCR-positive, culture-negative sample as
either a true positive or a false positive might not be possible.
No Food and Drug Administration (FDA)-licensed PCR test
kit and no national standardized protocols, reagents, and re-
porting formats are available. Approximately 100 different
PCR protocols have been reported. These vary by DNA puri-
fication techniques, PCR primers, reaction conditions, and
product detection methods (66). Laboratories must develop
and validate their own PCR tests. As a result, the analytical
sensitivity, accuracy, and quality control of PCR-based
B. pertussis tests can vary widely among laboratories. The
majority of laboratory validation studies have not sufficiently
established the predictive value of a positive PCR test to diag-
nose pertussis (66). Use of PCR tests with low specificity can
result in unnecessary investigation and treatment of persons
with false-positive PCR test results and inappropriate chemo-
prophylaxis of their contacts (66). CDC/Council of State and
Territorial Epidemiologists (CSTE) reporting guidelines sup-
port the use of PCR to confirm the diagnosis of pertussis
only when the case also meets the clinical case definition (>2
weeks of cough with paroxysms, inspiratory “whoop,” or
posttussive vomiting (68,69) (Appendix B).
Diagnosis of pertussis by serology generally requires dem-
onstration of a substantial change in titer for pertussis anti-
gens (usually fourfold) when comparing results from acute
(<2 weeks after cough onset) and convalescent sera (>4 weeks
after the acute sample). The results of serologic tests on paired
sera usually become available late in the course of illness. A
single sample serologic assay with age-specific antibody refer-
ence values is used as a diagnostic test for adolescents and
adults in Massachusetts but is not available elsewhere (70).
Other single sample serologic assays lack standardization and
do not clearly differentiate immune responses to pertussis
antigens following recent disease, from more remote disease,
or from vaccination (30). None of these serologic assays, in-
cluding the Massachusetts assay, is licensed by FDA for rou-
tine diagnostic use in the United States. For these reasons,
CDC guidelines for laboratory confirmation of pertussis cases
do not include serologic testing.
The only pertussis diagnostic tests that the CDC endorses
are culture and PCR (when the CDC/CSTE clinical case
definition is also met) (Appendix B). CDC-sponsored stud-
ies are under way to evaluate both serology and PCR testing.
CDC guidance on the use of pertussis diagnostics will be
updated as results of these studies become available.
Burden of Pertussis Among Adults
National Passive Surveillance
Pertussis has been a reportable disease in the United States
since 1922 (71). State health departments report confirmed
and probable cases of pertussis to CDC through the passive
National Notifiable Disease Surveillance System (NNDSS);
additional information on reported cases is collected through
the Supplemental Pertussis Surveillance System (SPSS) (Ap-
pendix B) (72,73). National passive reports provide informa-
tion on the national burden of pertussis and are used to
monitor national trends in pertussis over time.
After the introduction of routine vaccination against per-
tussis in the late 1940s, the number of national pertussis re-
ports declined from approximately 200,000 annual cases in
the prevaccine era (13) to a low of 1,010 cases reported in
1976 (Figure). Since then, a steady increase in the number of
reported cases has occurred; reports of cases among adults
and adolescents have increased disproportionately (72,74,75).
In 2004, 25,827 cases of pertussis were reported to the CDC
(9), the highest number since 1959. Adults aged 19–64 years
accounted for 7,008 (27%) cases (9). The increase in nationally
reported cases of pertussis during the preceding 15 years might
reflect a true increase in the burden of pertussis among adults or
the increasing availability and use of PCR to confirm cases and
increasing clinician awareness and reporting of pertussis (76).
Pertussis activity is cyclical with periodic increases every 3–
4 years (76,77). The typical periodicity has been less evident
in the last several years. However, during 2000–2004, the an-
nual incidence of pertussis from national reports in different
states varied substantially by year among adults aged 19–64
years (Table 5). The number of reports and the incidence of
pertussis among adults also varied considerably by state, a
reflection of prevailing pertussis activity and state surveillance
systems and reporting practices (72).
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Serosurveys and Prospective Studies
In contrast to passively reported cases of pertussis,
serosurveys and prospective population-based studies dem-
onstrate that B. pertussis infection is relatively common among
adults with acute and prolonged cough illness and is even
more common when asymptomatic infections are considered.
These studies documented higher rates of pertussis than those
derived from national passive surveillance reports in part be-
cause some diagnostic or confirmatory laboratory tests were
available only in the research setting and because study sub-
jects were tested for pertussis early in the course of their cough
illness when recovery of B. pertussis is more likely. These stud-
ies provide evidence that national passive reports of adult per-
tussis constitute only a small fraction (approximately 1%–2%)
of illness among adults caused by B. pertussis (78).
During the late 1980s and early 1990s, studies using sero-
logic diagnosis of B. pertussis infection estimated rates of re-
cent B. pertussis infection between 8%–26% among adults
with cough illness of at least 5 days duration who sought
medical care (79–84). In a serosurvey conducted over a 3-
year period among elderly adults, serologically defined epi-
sodes of infection occurred at a rate of 3.3–8.0 per 100
person-years, depending on diagnostic criteria (85). The preva-
lence of recent B. pertussis infection was an estimated 2.9%
among participants aged 10–49 years in a nationally repre-
sentative sample of the U.S. civilian, noninstitutionalized
population (86). Another study determined infection rates
among healthy persons aged 15–65 years to be approximately
1% during 11-month period (87). The proportion of B. pertussis
infections that are symptomatic in studies was between 10%–
70% depending on the setting, the population, and diagnostic
criteria employed (28,87–89).
Four prospective, population-based studies estimate the
annual incidence of pertussis among adults in the United States
(Table 6). Two were conducted in health maintenance orga-
nizations (HMO) (83,84), one determined the annual inci-
dence of pertussis among subjects enrolled in the control arm
of a clinical trial of acellular pertussis vaccine (28), and one
was conducted among university students (80). From a re-
analysis of the database of the Minnesota HMO study, the
annual incidence of pertussis by decade of age on the basis of
15 laboratory-confirmed cases of pertussis was 229 (CI = 0–
540), 375 (CI = 54–695) and 409 (CI = 132–686) per 100,000
population for adults aged 20–29, 30–39, and 40–49 years,
respectively (CDC, unpublished data, 2005). When applied
to the U.S. population, estimates from the three prospective
studies suggest the number of cases of symptomatic pertussis
among adults aged 19–64 years could range from 299,000 to
626,000 cases annually in the United States (78).
Pertussis Outbreaks Involving Adults
Pertussis outbreaks involving adults occur in the commu-
nity and the workplace. During an outbreak in Kent County,
Michigan in 1962, the attack rate among adults aged >20
years in households with at least one case of pertussis was
21%; vulnerability to pertussis appeared unrelated to previ-
ous vaccination or history of pertussis in childhood (3). In a
statewide outbreak in Vermont in 1996, a total of 65 (23%)
of 280 cases occurred among adults aged >20 years (90); in a
2003 Illinois outbreak, 64 (42%) of 151 pertussis cases oc-
curred among adults aged >20 years (91). Pertussis outbreaks
are regularly documented in schools and health-care settings
and occasionally in other types of workplaces (e.g., among
employees of an oil refinery [92]). In school outbreaks, the
majority of cases occur among students. However, teachers
who are exposed to students with pertussis also are infected
(90,93,94). In a Canadian study, teachers were at approxi-
mately a fourfold higher risk for pertussis compared with the
general population during a period when high rates of per-
tussis occurred among adolescents (41).
Background: Tetanus and Diphtheria
Tetanus
Tetanus is unique among diseases for which vaccination is
routinely recommended because it is noncommunicable.
Clostridium tetani spores are ubiquitous in the environment
TABLE 5. Annual number and incidence of reported pertussis cases among adults aged 19–64 years — selected states, 2000–
2004*
High year Low year
Annual Annual
State Cases incidence† Cases incidence†
Wisconsin 1,867 55.6 18 0.5
Massachusetts 666 16.6 181 4.5
Minnesota 297 9.5 50 1.6
Vermont 38 9.7 20 5.1
*Source: CDC. National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System, 2000–2004.
†Per 100,000 population.
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and enter the body through nonintact skin. When inoculated
into oxygen-poor sites, such as necrotic tissue that can result
from blunt trauma or deep puncture wounds, C. tetani spores
germinate to vegetative bacilli that multiply and elaborate teta-
nospasmin, a potent neurotoxin. Generalized tetanus typi-
cally presents with trismus (lockjaw), followed by generalized
rigidity caused by painful contractions of the skeletal muscles
that can impair respiratory function. Glottic spasm, respira-
tory failure, and autonomic instability can result in death (95).
During 1998–2000, the case-fatality ratio for reported teta-
nus was 18% in the United States (96,97).
Following the introduction and widespread use of tetanus
toxoid vaccine in the United States, tetanus became uncom-
mon. From 1947, when national reporting began, through
1998–2000, the incidence of reported cases declined from
3.9 to 0.16 cases per million population (96,97). Older adults
have a disproportionate burden of illness from tetanus. Dur-
ing 1990–2001, a total of 534 cases of tetanus were reported;
301 (56%) cases occurred among adults aged 19–64 years
and 201 (38%) among adults aged >65 years (CDC, unpub-
lished data, 2005). Data from a national population-based
serosurvey conducted in the United States during 1988–1994
indicated that the prevalence of immunity to tetanus, defined
as a tetanus antitoxin concentration of >0.15 IU/mL, was
>80% among adults aged 20–39 years and declined with in-
creasing age. Forty-five percent of men and 21% of women
aged >70 years had protective levels of antibody to tetanus
(98). The low prevalence of immunity and high proportion
of tetanus cases among older adults might be related to the
high proportion of older adults, especially women, who never
received a primary series (96,97).
Neonatal tetanus usually occurs as a result of C. tetani in-
fection of the umbilical stump. Susceptible infants are born
to mothers with insufficient maternal tetanus antitoxin con-
centration to provide passive protection (95). Neonatal teta-
nus is rare in the United States. Three cases were reported
during 1990–2004 (CDC, unpublished data, 2005). Two of
the infants were born to mothers who had no dose or only
one dose of a tetanus toxoid-containing vaccine (99,100); the
vaccination history of the other mother was unknown (CDC,
unpublished data, 2005). Well-established evidence supports
the recommendation for tetanus toxoid vaccine during preg-
nancy for previously unvaccinated women (33,95,103–105).
During 1999, a global maternal and neonatal tetanus elimi-
nation goal was adopted by the World Health Organization,
the United Nations Children’s Fund, and the United Nations
Population Fund (104).
Diphtheria
Respiratory diphtheria is an acute and communicable in-
fectious illness caused by strains of Corynebacterium diphtheriae
and rarely by other corynebacteria (e.g., C. ulcerans) that pro-
duce diphtheria toxin; disease caused by C. diphtheriae and
other corynebacteria are preventable through vaccination with
diphtheria toxoid-containing vaccines. Respiratory diphthe-
TABLE 6. Estimated annual incidence of pertussis among adolescents and adults in prospective studies
Estimated annual
No. positive/ incidence per 100,000
No. no. tested, person-years
Study design confirmed Minimum cough by type of (95% confidence
Reference and setting cases Population duration diagnostic test interval (CI)
Strebel* Prospective case 15 adults aged 155 adults aged Acute cough: 8/8 culture 361†
series (health 20–49 years 20–49 years  7–28 days 10/13 polymerase (adults aged 20–49)
maintenance Paroxysmal cough: chain reaction (PCR) (CI = 176–546)
organization [HMO)] 7 days 11/15 fourfold rise in
IgG antibody to
pertussis toxin
Ward§ Multicenter, 9 1,390 persons Acute cough: 4/9 culture 368
randomized, aged 15–65 5 days 5/9 PCR (CI = 168–699)†
double-blind years in control 9/9 serology
controlled trial arm of vaccine
efficacy trial
Nennig¶ Prospective clinical 19 153 adults Acute cough: 19/19 IgG antibody 176
study-HMO aged >18 years >2 weeks to pertussis toxin (CI = 97–255)
Mink** Prospective case- 34 130 university Cough illness: 0/34 culture 69
control study students >6 days 1/34 direct (Not available)
(university) fluorescent antibody
33/34 serology
* Source: Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. J Infect Dis 2001;183:
1353–9.
† Source: Cortese MM, Baughman AL, Brown K, Srivastava P. A new age in pertussis prevention—new opportunities through adult vaccination. Am J Prev Med 2007 (In press).
§ Source: Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555–63.
¶ Source: Nennig ME, Shinefield HR, Edwards KM, Black SB, Fireman BH. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996;275:1672–4.
** Source: Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464–71.
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ria is characterized by a grayish colored, adherent membrane
in the pharynx, palate, or nasal mucosa that can obstruct the
airway. Toxin-mediated cardiac and neurologic systemic com-
plications can occur (105,106).
Reports of respiratory diphtheria are rare in the United States
(107,108). During 1998–2004, seven cases of respiratory
diphtheria were reported to CDC (9,10). The last culture-
confirmed case of respiratory diphtheria caused by C.
diphtheriae in an adult aged >19 years was reported in 2000
(108). A case of respiratory diphtheria caused by C. ulcerans
in an adult was reported in 2005 (CDC, unpublished data,
2005). Data obtained from the national population-based
serosurvey conducted during 1988–1994 indicated that the
prevalence of immunity to diphtheria, defined as a diphthe-
ria antitoxin concentration of >0.1 IU/mL, progressively de-
creased with age from 91% at age 6–11 years to approximately
30% by age 60–69 years (98).
Adherence to the ACIP-recommended schedule of decen-
nial Td boosters in adults is important to prevent sporadic
cases of respiratory diphtheria and to maintain population
immunity (33). Exposure to diphtheria remains possible dur-
ing travel to countries in which diphtheria is endemic (infor-
mation available at www.cdc.gov/travel/diseases/dtp.htm),
from imported cases, or from rare endemic diphtheria
toxin-producing strains of corynebacteria other than C.
diphtheriae (106). The clinical management of diphtheria, in-
cluding use of diphtheria antitoxin, and the public health re-
sponse is reviewed elsewhere (33,106,109).
Adult Acellular Pertussis Vaccine
Combined with Tetanus
and Diphtheria Toxoids
In the United States, one Tdap product is licensed for use
in adults and adolescents. ADACEL® (sanofi pasteur, Toronto,
Ontario, Canada) was licensed on June 10, 2005, for use in
persons aged 11–64 years as a single dose active booster vacci-
nation against tetanus, diphtheria, and pertussis (11). Another
Tdap product, BOOSTRIX® (GlaxoSmithKline, Rixensart,
Belgium), is licensed for use in adolescents but not for use among
persons aged >19 years (20).
ADACEL®
ADACEL® contains the same tetanus toxoid, diphtheria
toxoid, and five pertussis antigens as those in DAPTACEL®
(pediatric DTaP), but ADACEL® is formulated with reduced
quantities of diphtheria toxoid and detoxified pertussis toxin
(PT). Each antigen is adsorbed onto aluminum phosphate.
Each dose of ADACEL® (0.5 mL) is formulated to contain 5
Lf [limit of flocculation unit] of tetanus toxoid, 2 Lf diphthe-
ria toxoid, 2.5 µg detoxified PT, 5 µg filamentous hemagglu-
tinin (FHA), 3 µg pertactin (PRN), and 5 µg fimbriae types 2
and 3 (FIM). Each dose also contains aluminum phosphate
(0.33 mg aluminum) as the adjuvant, <5 µg residual formal-
dehyde, <50 ng residual glutaraldehyde, and 3.3 mg 2-
phenoxyethanol (not as a preservative) per 0.5-mL dose.
ADACEL® contains no thimerosal. ADACEL® is available
in single dose vials that are latex-free (11).
ADACEL® was licensed for adults on the basis of clinical
trials demonstrating immunogenicity not inferior to U.S.-
licensed Td or pediatric DTaP (DAPTACEL®, made by the
same manufacturer) and an overall safety profile clinically
comparable with U.S.-licensed Td (11,20). In a noninferiority
trial, immunogenicity, efficacy, or safety endpoints are dem-
onstrated when a new product is at least as good as a com-
parator on the basis of a predefined and narrow margin for a
clinically acceptable difference between the study groups (110).
Adolescents aged 11–17 years also were studied; these results
are reported elsewhere (12,111,112).
Immunogenicity
A comparative, observer-blinded, multicenter, randomized
controlled clinical trial conducted in the United States evalu-
ated the immunogenicity of the tetanus toxoid, diphtheria
toxoid , and pertussis antigens among adults aged 18–64 years
(11,111,112). Adults were randomized 3:1 to receive a single
dose of ADACEL® or a single dose of U.S.-licensed Td (manu-
factured by sanofi pasteur; contains tetanus toxoid [5 Lf ] and
diphtheria toxoid [2 Lf ]) (11,111). Sera from a subset of per-
sons were obtained before and approximately 1 month after
vaccination (11). All assays were performed at the immunol-
ogy laboratories of sanofi pasteur in Toronto, Ontario, Canada,
or Swiftwater, Pennsylvania, using validated methods (111,112).
Adults aged 18–64 years were eligible for enrollment if they
were in good health; adults aged >65 years were not included
in prelicensure studies. Completion of the childhood DTP/
DTaP vaccination series was not required. Persons were ex-
cluded if they had received a tetanus, diphtheria, or pertussis
vaccine within 5 years; had a diagnosis of pertussis within 2
years; had an allergy or sensitivity to any vaccine component;
had a previous reaction to a tetanus, diphtheria, or pertussis
vaccine, including encephalopathy within 7 days or seizures
within 3 days of vaccination; had an acute respiratory illness
on the day of enrollment; had any immunodeficiency, sub-
stantial underlying disease, or neurologic impairment; had
daily use of oral, nonsteroidal anti-inflammatory drugs; had
received blood products or immunoglobulins within 3
months; or were pregnant (11,112) (sanofi pasteur, unpub-
lished data, 2005).
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Tetanus and Diphtheria Toxoids
The efficacy of the tetanus toxoid and the diphtheria tox-
oid components of ADACEL® was inferred from the immu-
nogenicity of these antigens using established serologic
correlates of protection (95,105). Immune responses to teta-
nus and diphtheria antigens were compared between the
ADACEL® and Td groups, with 739–742 and 506–509 per-
sons, respectively. One month postvaccination, the tetanus
antitoxin seroprotective (>0.1 IU/mL) and booster response
rates among adults who received ADACEL® were noninferior
to those who received Td. The seroprotective rate for tetanus
was 100% (CI = 99.5%–100%) in the ADACEL® group and
99.8% (CI = 98.9%–100%) in the Td group. The booster
response rate to tetanus* in the ADACEL® group was 63.1%
(CI = 59.5%–66.6%) and 66.8% (CI = 62.5%–70.9%) in
the Td group (11,111). One month postvaccination the diph-
theria antitoxin seroprotective (>0.1 IU/mL) and booster re-
sponse rates* among adults who received a single dose of
ADACEL® were noninferior to those who received Td. The
seroprotective rate for diphtheria was 94.1% (CI = 92.1%–
95.7%) in the ADACEL® group and 95.1% (CI = 92.8%–
96.8%) in the Td group. The booster response rate to diphtheria*
in the ADACEL® group was 87.4% (CI = 84.8%–89.7%) and
83.4% (CI = 79.9%–86.5%) in the Td group (11,111).
Pertussis Antigens
In contrast to tetanus and diphtheria, no well-accepted se-
rologic or laboratory correlate of protection for pertussis ex-
ists (113). A consensus was reached at a 1997 meeting of the
Vaccines and Related Biological Products Advisory Commit-
tee (VRBPAC) that clinical endpoint efficacy studies of acel-
lular pertussis vaccines among adults were not required for
Tdap licensure. Rather, the efficacy of the pertussis compo-
nents of Tdap administered to adults could be inferred using
a serologic bridge to infants vaccinated with pediatric DTaP
during clinical endpoint efficacy trials for pertussis (114). The
efficacy of the pertussis components of ADACEL® was evalu-
ated by comparing the immune responses (geometric mean
antibody concentration [GMC]) of adults vaccinated with a
single dose of ADACEL® to the immune responses of infants
vaccinated with 3 doses of DAPTACEL® in a Swedish vac-
cine efficacy trial during the 1990s (11,115). ADACEL® and
DAPTACEL® contain the same five pertussis antigens, ex-
cept ADACEL® contains one fourth the quantity of detoxi-
fied PT in DAPTACEL® (116). In the Swedish trial, efficacy
of 3 doses of DAPTACEL® against World Health Organization-
defined pertussis (>21 days of paroxysmal cough with confir-
mation of B. pertussis infection by culture and serologic testing
or an epidemiologic link to a household member with cul-
ture-confirmed pertussis) was 85% (CI = 80%–89%)
(11,115). The percentage of persons with a booster response
to vaccine pertussis antigens exceeding a predefined lower limit
for an acceptable booster response also was evaluated. The
anti-PT, anti-FHA, anti-PRN, and anti-FIM GMCs of adults
1 month after a single dose of ADACEL® were noninferior to
those of infants after 3 doses of DAPTACEL® (Table 7) (11).
Booster response rates to the pertussis antigens† contained in
ADACEL® (anti-PT, anti-FHA, anti-PRN, and anti-FIM)
among 739 adults 1 month following administration of
ADACEL® met prespecified criteria for an acceptable response.
Booster response rates to pertussis antigens were: anti-PT, 84.4%
(CI = 81.6%–87.0%); anti-FHA, 82.7% (CI = 79.8%–85.3%);
anti-PRN, 93.8% (CI = 91.8%–95.4%); and anti-FIM 85.9%
(CI = 83.2%–88.4%) (11,112).
* Booster response defined as a fourfold rise in antibody concentration if the
prevaccination concentration was equal to or below the cutoff value and a
twofold rise in antibody concentration if the prevaccination concentration
was above the cutoff value. The cutoff value for tetanus was 2.7 IU/mL. The
cutoff value for diphtheria was 2.56 IU/mL.
† A booster response for each antigen was defined as a fourfold rise in antibody
concentration if the prevaccination concentration was equal to or below the
cutoff value and a twofold rise in antibody concentration if the prevaccination
concentration was above the cutoff value. The cutoff values for pertussis
antigens were 85 EU/mL for PT, 170 EU/mL for FHA, 115 EU/mL for
PRN, and 285 EU/mL for FIM.
TABLE 7. Ratio of pertussis antibody geometric mean
concentrations (GMCs) observed in adults 1 month after a
dose of  ADACEL® compared with those observed in infants
1 month after 3 doses of DAPTACEL® at ages 2, 4, and 6
months*
GMC ratio:
GMC ADACEL® / GMC DAPTACEL®
Antibody (95% confidence interval)





Sources: Food and Drug Administration. Product approval information
licensing action, package insert: Tetanus Toxoid, Reduced Diphtheria
Toxoid and Acellular Pertussis Vaccine Adsorbed ADACEL®, sanofi
pasteur. Rockville, MD: US Department of Health and Human Services,
Food and Drug Administration, Center for Biologics Evaluation and
Research; 2006. Available at http://www.fda.gov/cber/label/
tdapave012306LB.pdf. Food and Drug Administration. Vaccines and
Related Biological Products Advisory Committee, March 15, 2005; FDA
ADACEL® briefing information. Rockville, MD: US Department of Health
and Human Services, Food and Drug Administration; 2005. Available
at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1_4a.pdf.
Picchichero ME, Rennels MB, Edwards KM, et al. Combined tetanus,
diphtheria, and 5-component pertussis vaccine for use in adolescents
and adults. JAMA 2005;293:3003–11.
* Populations studied: U.S. adults (n = 741) and Swedish infants (n = 80)
(on the basis of number with evaluable data for each antigen).
† GMC after ADACEL® was noninferior to GMC following DAPTACEL®
(lower limit of the 95% confidence interval on the ratio of ADACEL®
divided by DAPTACEL® >0.67).
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Safety
The primary adult safety study, conducted in the United
States, was a randomized, observer-blinded, controlled study
of 1,752 adults aged 18–64 years who received a single dose
of ADACEL®, and 573 who received Td. Data on solicited
local and systemic adverse events were collected using stan-
dardized diaries for the day of vaccination and the next 14
consecutive days (i.e., within 15 days following vaccination)
(11).
Immediate Events
Five adults experienced immediate events within 30 min-
utes of vaccination (ADACEL® [four persons] and Td [one]);
all incidents resolved without sequelae. Three of these events
were classified under nervous system disorders (hypoesthesia/
paresthesia). No incidents of syncope or anaphylaxis were re-
ported (111,112,116).
Solicited Local Adverse Events
Pain at the injection site was the most frequently reported
local adverse event among adults in both vaccination groups
(Table 8). Within 15 days following vaccination, rates of any
pain at the injection site were comparable among adults vac-
cinated with ADACEL® (65.7%) and Td (62.9%). The rates
of pain, erythema, and swelling were noninferior in the
ADACEL® recipients compared with the Td recipients
(Table 8) (11,111). No case of whole-arm swelling was re-
ported in either vaccine group (112).
Solicited Systemic Adverse Events
The most frequently reported systemic adverse events dur-
ing the 15 days following vaccination were headache, gener-
alized body aches, and tiredness (Table 9). The proportion of
adults reporting fever >100.4°F (38°C) following vaccination
were comparable in the ADACEL® (1.4%) and Td (1.1%)
groups, and the noninferiority criterion for ADACEL® was
achieved. The rates of the other solicited systemic adverse
events also were comparable between the ADACEL® and Td
groups (11).
Serious Adverse Events
Serious adverse events (SAEs) within 6 months after vacci-
nation were reported among 1.9% of the vaccinated adults:
33 of 1,752 in the ADACEL® group and 11 of the 573 in the
Td group (111,116). Two of these SAEs were neuropathic
events in ADACEL® recipients and were assessed by the in-
vestigators as possibly related to vaccination. A woman aged
23 years was hospitalized for a severe migraine with unilateral
facial paralysis 1 day following vaccination. A woman aged
49 years was hospitalized 12 days after vaccination for symp-
toms of radiating pain in her neck and left arm (vaccination
arm); nerve compression was diagnosed. In both cases, the
symptoms resolved completely over several days
(11,111,112,116). One seizure event occurred in a woman
aged 51 years 22 days after ADACEL® and resolved without
sequelae; study investigators reported this event as unrelated
to vaccination (116). No physician-diagnosed Arthus reac-
tion or case of Guillian-Barré syndrome was reported in any
ADACEL® recipient, including the 1,184 adolescents in the
adolescent primary safety study (sanofi pasteur, unpublished
data, 2005).
Comparison of Immunogenicity and Safety
Results Among Age Groups
Immune responses to the antigens in ADACEL® and Td in
adults (aged 18–64 years) 1 month after vaccination were
comparable to or lower than responses in adolescents (aged
11–17 years) studied in the primary adolescent prelicensure
trial (111). All adults in three age strata (18–28, 29–48, 49–
TABLE 8. Frequencies of solicited local adverse events
among adults within 15 days* after a single dose of ADACEL®
or Td
ADACEL® (%) Td (%)
Event Intensity (N = 1698)† (N = 561) †
Pain§ Any 65.7 62.9
Moderate 15.1 10.2
Severe 1.1 0.9
Erythema¶ Any 24.7 21.6
Moderate 8.0 8.4
Severe 6.2 4.8
Swelling¶ Any 21.0 17.3
Moderate 7.6 5.4
Severe 5.8 5.5
Underarm lymph node Any 6.5 4.1
swelling§ Moderate 1.2 0.5
Severe 0.1 0
Sources:  Food and Drug Administration. Product approval
information”licensing action, package insert: Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed ADACEL®,
sanofi pasteur. Rockville, MD: US Department of Health and Human
Services, Food and Drug Administration, Center for Biologics Evaluation
and Research; 2006. Available at http://www.fda.gov/cber/label/
tdapave012306LB.pdf. Food and Drug Administration. Vaccines and
Related Biological Products Advisory Committee, March 15, 2005; FDA
ADACEL® briefing information. Rockville, MD: US Department of Health
and Human Services, Food and Drug Administration; 2005. Available
at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1_4a.pdf.
Picchichero ME, Rennels MB, Edwards KM, et al. Combined tetanus,
diphtheria, and 5-component pertussis vaccine for use in adolescents
and adults. JAMA 2005;293:3003–11.
* Vaccination day and the following 14 days.
†Number of persons with available data.
§Pain at injection site and lymph node swelling each defined as: Mild:
noticeable but did not interfere with activities (not shown in table);
Moderate: interfered with activities but did not require medical attention/
absenteeism; Severe: incapacitating, unable to perform usual activities,
may have or did necessitate medical care or absenteeism; Any: Mild,
moderate, and severe.
¶ Erythema and swelling: Mild: <10 mm; Moderate: 10–34 mm; Severe:
>35 mm; Any: Mild, moderate, and severe.
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64 years) achieved a seroprotective antibody level for tetanus
after ADACEL®. Seroprotective responses to diphtheria fol-
lowing ADACEL® were comparable among adolescents
(99.8%) and young adults aged 18–28 years (98.9%) but were
lower among adults aged 49–64 years (85.4%) (111). Gener-
ally, adolescents had better immune response to pertussis an-
tigens than adults after receipt of ADACEL®, although GMCs
in both groups were higher than those of infants vaccinated
in the DAPTACEL® vaccine efficacy trial. Immune response
to PT and FIM decreased with increasing age in adults; no
consistent relation between immune responses to FHA or PRN
and age was observed (111).
Overall, local and systemic events after ADACEL® vacci-
nation were less frequently reported by adults than adoles-
cents. Pain, the most frequently reported adverse event in the
studies, was reported by 77.8% of adolescents and 65.7% of
adults vaccinated with ADACEL®. Fever was also reported
more frequently by adolescents (5%) than adults (1.4%) vac-
cinated with ADACEL® (11,111). In adults, a trend for de-
creased frequency of local adverse events in the older age groups
was observed.
Simultaneous Administration of ADACEL® with
Other Vaccines
Trivalent Inactivated Influenza Vaccine
Safety and immunogenicity of ADACEL® co-
administered with trivalent inactivated influenza vaccine
([TIV] Fluzone®, sanofi pasteur, Swiftwater, Pennsylvania)
was evaluated in adults aged 19–64 years using methods similar
to the primary ADACEL® studies. Adults were randomized
into two groups. In one group, ADACEL® and TIV were
administered simultaneously in different arms (N = 359). In
the other group, TIV was administered first, followed by
ADACEL® 4–6 weeks later (N = 361).
The antibody responses (assessed 4–6 weeks after vaccina-
tion) to diphtheria, three pertussis antigens (PT, FHA, and
FIM), and all influenza antigens§ were noninferior in per-
sons vaccinated simultaneously with ADACEL® compared
with those vaccinated sequentially (TIV first, followed by
ADACEL®).¶ For tetanus, the proportion of persons achiev-
ing a seroprotective antibody level was noninferior in the si-
multaneous group (99.7%) compared with the sequential
group (98.1%). The booster response rate to tetanus in the
simultaneous group (78.8%) was lower than the sequential
group (83.3%), and the noninferiority criterion for simulta-
neous vaccination was not met. The slightly lower propor-
tion of persons demonstrating a booster response to tetanus
in the simultaneous group is unlikely to be clinically impor-
tant because >98% of subjects in both group groups achieved
TABLE 9. Frequencies of solicited systemic adverse events
among adults within 15 days* after a single dose of ADACEL®
or Td
ADACEL® (%) Td (%)
Event† Intensity (N = 1,688–1,698)§ (N = 551–560)§
Fever Any 1.4 1.1
Moderate 0.4 0.2
Severe 0 0.2
Chills Any 8.1 6.6
Moderate 1.3 1.6
Severe 0.7 0.5
Headache Any 33.9 34.1
Moderate 11.4 10.5
Severe 2.8 2.1
Generalized Any 21.9 18.8
body ache Moderate 6.1 5.7
Severe 1.2 0.9
Tiredness Any 24.3 20.7
Moderate 6.9 6.1
Severe 1.3 0.5
Nausea Any 9.2 7.9
Moderate 2.5 1.8
Severe 0.8 0.5
Vomiting Any 3.0 1.8
Moderate 1.0 0.9
Severe 0.5 0.2
Diarrhea Any 10.3 11.3
Moderate 2.2 2.7
Severe 0.5 0.5
Sore and/or Any 9.1 7.0
swollen joints Moderate 2.5 2.1
Severe 0.5 0.5
Rash Any 2.0 2.3
Sources:  Food and Drug Administration. Product approval
information”licensing action, package insert: Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed ADACEL®,
sanofi pasteur. Rockville, MD: US Department of Health and Human
Services, Food and Drug Administration, Center for Biologics Evaluation
and Research; 2006. Available at http://www.fda.gov/cber/label/
tdapave012306LB.pdf. Food and Drug Administration. Vaccines and
Related Biological Products Advisory Committee, March 15, 2005; FDA
ADACEL® briefing information. Rockville, MD: US Department of Health
and Human Services, Food and Drug Administration; 2005. Available
at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4097B1_4a.pdf.
Picchichero ME, Rennels MB, Edwards KM, et al. Combined tetanus,
diphtheria, and 5-component pertussis vaccine for use in adolescents
and adults. JAMA 2005;293:3003–11.
* Vaccination day and the following 14 days.
† Fever: Mild: >100.4°F (>38°C) to <101.9°F (<38.8°C); Moderate:
>102.0°F (>38.9°C) to <103.0°F (<39.4°C); Severe: >103.1°F (>39.5°C).
Chills, headache, generalized bodyache, tiredness, nausea, vomiting,
diarrhea, sore (and/or swollen) joints: Mild: noticeable but did not interfere
with activities; Moderate: interfered with activities but did not require
medical attention/absenteeism; Severe: incapacitating, unable to
perform usual activities, may have or did necessitate medical care or
absenteeism; Any: Mild + Moderate + Severe.
§ Number of persons with available data.
§ A hemagglutinin inhibition titer >1:40 IU/mL for each influenza antigen
was considered seropositive.
¶ The noninferiority criterion was met if the upper limit of the 95% confidence
interval on the difference in the percentage of subjects in the two groups
(rate following simultaneous vaccination minus rate following sequential
vaccination) was <10%.
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seroprotective levels. The immune response to PRN pertussis
antigen in the simultaneous group did not meet noninferiority
criterion when compared with the immune response in the
sequential group (111). The lower limit of the 90% CI on the
ratio of the anti-PRN GMCs (simultaneous vaccination group
divided by the sequential vaccination group) was 0.61, and
the noninferiority criterion was >0.67; the clinical importance
of this finding is unclear (111).
Adverse events were solicited only after ADACEL® (not
TIV) vaccination (111). Within 15 days of vaccination, rates
of erythema, swelling, and fever were comparable in both vac-
cination groups (Table 10). However, the frequency of pain
at the ADACEL® injection site was higher in the simulta-
neous group (66.6%) than the sequential group (60.8%), and
the noninferiority for simultaneous vaccination was not
achieved (111).
Hepatitis B Vaccine
Safety and immunogenicity of ADACEL® administered
with hepatitis B vaccine was not studied in adults but was
evaluated among adolescents aged 11–14 years using meth-
ods similar to the primary ADACEL® studies. Adolescents
were randomized into two groups. In one group, ADACEL®
and hepatitis B vaccine (Recombivax HB®, Merck and Co.,
White House Station, New Jersey) were administered simul-
taneously (N = 206). In the other group, ADACEL® was
administered first, followed by hepatitis B vaccine 4–6 weeks
later (N = 204). No interference was observed in the immune
responses to any of the vaccine antigens when ADACEL®
and hepatitis B vaccine were administered simultaneously or
sequentially** (11).
Adverse events were solicited only after ADACEL® vacci-
nation (not hepatitis B vaccination) (111). Within 15 days of
vaccination, the reported rates of injection site pain (at the
ADACEL® site) and fever were comparable when ADACEL®
and hepatitis B vaccine were administered simultaneously or
sequentially (Table 11). However, rates of erythema and swell-
ing at the ADACEL® injection site were higher in the simul-
taneous group, and noninferiority for simultaneous
vaccination was not achieved. Swollen and/or sore joints were
reported in 22.5% of persons who received simultaneous vac-
cination, and in 17.9% of persons in the sequential group.
The majority of joint complaints were mild in intensity with
a mean duration of 1.8 days (11).
Other Vaccines
Safety and immunogenicity of simultaneous administration
of ADACEL® with other vaccines were not evaluated during
prelicensure studies (11).
** An antihepatitis B surface antigen of >10 mIU/mL was considered
seroprotective.
TABLE 10. Frequencies of selected solicited local and systemic adverse events for adults aged 19–64 years after simultaneous
and sequential administration of trivalent activated influenza vaccine (TIV) and ADACEL®
Sequential group
Simultaneous group TIV followed by ADACEL®
ADACEL® and TIV (%) 4–6 weeks later (%)
Type of adverse event (N = 352–356)* (N = 336–340)*
Immediate event 0.8 0.3
Solicited local event at the Tdap injection site† 69.1 64.1
       Erythema, any§ 10.8 12.4
       Swelling, any§ 15.3 10.3
       Pain, any¶ 66.6** 60.8
       Pain, moderate and severe¶ 13.3** 7.1
Any solicited systemic event† 61.5 56.2
      Fever >100.4°F  (>38°C)§ 4.3† 2.4
       Sore and/or swollen joints§ 12.5 9.4
SOURCE: Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee, March 15, 2005; FDA ADACEL® briefing
information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/
ohrms/dockets/ac/05/briefing/2005-4097B1_4a.pdf.
* Number of persons with available data.
† Vaccination day and the following 14 days.
§ Rates of erythema, swelling, and fever for simultaneous vaccination were noninferior to rates for sequential vaccination.
¶ Pain at injection site defined as Mild: noticeable but did not interfere with activities; Moderate: interfered with activities but did not require medical
attention/absenteeism; Severe: incapacitating, unable to perform usual activities, may have or did necessitate medical care or absenteeism; Any:  Mild,
moderate, and severe.
** Rates of “any” pain and “moderate and severe pain” for simultaneous vaccination did not meet noninferiority criterion compared with the rates in the
sequential group. The upper limit of the 95% confidence interval on the difference in the percentage of subjects in the two groups (rate following
simultaneous vaccination minus rate following sequential vaccination) was 13.0% for any pain and 10.7% for moderate and severe pain; the noninferiority
criterion was <10%.
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Safety Considerations for Adult
Vaccination with Tdap
Tdap prelicensure studies in adults support the safety of
ADACEL® (11). However, sample sizes were insufficient to
detect rare adverse events. Enrollment criteria excluded per-
sons who had received vaccines containing tetanus toxoid,
diphtheria toxoid, and/or pertussis components during the
preceding 5 years (111,112). Persons with certain neurologic
conditions were excluded from prelicensure studies. There-
fore, in making recommendations on the spacing and admin-
istration sequence of vaccines containing tetanus toxoid,
diphtheria toxoid, and/or pertussis components and on vac-
cination of adults with a history of certain neurologic condi-
tions or previous adverse events after vaccination, ACIP
considered data from a range of pre- and postlicensure stud-
ies of Tdap and other vaccines containing these components.
Safety data from the Vaccine Adverse Event Reporting System
(VAERS) and postlicensure studies are monitored on an ongo-
ing basis and will facilitate detection of potential adverse reac-
tions following more widespread use of Tdap in adults.
Spacing and Administration Sequence
of Vaccines Containing Tetanus Toxoid,
Diphtheria Toxoid, and Pertussis Antigens
Historically, moderate and severe local reactions following
tetanus and diphtheria toxoid-containing vaccines have been
associated with older, less purified vaccines, larger doses of
toxoid, and frequent dosing at short intervals (117–122). In
addition, high pre-existing antibody titers to tetanus or diph-
theria toxoids in children, adolescents, and adults primed with
these antigens have been associated with increased rates for
local reactions to booster doses of tetanus or diphtheria tox-
oid-containing vaccines (119,122–124). Two adverse events
of particular clinical interest, Arthus reactions and extensive
limb swelling (ELS), have been associated with vaccines con-
taining tetanus toxoid, diphtheria toxoid, and/or pertussis
antigens.
Arthus Reactions
Arthus reactions (type III hypersensitivity reactions) are
rarely reported after vaccination and can occur after tetanus
toxoid-containing or diphtheria toxoid-containing vaccines
(33,122,125–129; CDC, unpublished data, 2005). An Arthus
reaction is a local vasculitis associated with deposition of im-
mune complexes and activation of complement. Immune
complexes form in the setting of high local concentration of
vaccine antigens and high circulating antibody concentration
(122,125,126,130). Arthus reactions are characterized by se-
vere pain, swelling, induration, edema, hemorrhage, and oc-
casionally by local necrosis. These symptoms and signs usually
develop 4–12 hours after vaccination; by contrast, anaphy-
laxis (immediate type I hypersensitivity reactions) usually oc-
cur within minutes of vaccination. Arthus reactions usually
resolve without sequelae. ACIP has recommended that per-
TABLE 11. Frequencies of selected solicited local and systemic adverse events for adolescents aged 11–14 years after
simultaneous and sequential administration of ADACEL® and hepatitis B vaccine
Simultaneous group Sequential group
ADACEL® and ADACEL® followed by hepatitis
hepatitis B (%) B vaccine 4–6 weeks later (%)
Type of adverse event (N = 201–202)* (N = 200–201)*
Immediate event 0.5 2.0




Pain, any¶ 85.6 85.1
Pain, moderate and severe¶ 19.9 23.4
Any solicited systemic event† 79.2 74.6
Sore and/or swollen joints§ 22.5 17.9
Fever >100.4°F (>38°C) 5.5 6.0
Source: Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee, March 15, 2005; FDA clinical briefing document
for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap, ADACEL™), Aventis Pasteur, Limited. Rockville, MD:
US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/
2005-4097B1_4a.pdf.
* Number of persons with available data.
† Vaccination day and the following 14 days.
§ The noninferiority criteria were not achieved for rates of erythema and swelling following simultaneous vaccination compared with the rates following
sequential vaccination. The upper limit of the 95% confidence interval on the difference in the percentage of persons (simultaneous vaccination minus
sequential vaccination) was 10.1% (erythema) and 13.9% (swelling) whereas the criteria were <10%.
¶ Pain at injection site defined as Mild: noticeable but did not interfere with activities; Moderate: interfered with activities but did not require medical
attention/absenteeism; Severe: incapacitating, unable to perform usual activities, might have or did necessitate medical care or absenteeism; Any:
Mild, moderate, and severe.
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sons who experienced an Arthus reaction after a dose of teta-
nus toxoid-containing vaccine not receive Td more frequently
than every 10 years, even for tetanus prophylaxis as part of
wound management (12,33).
Extensive Limb Swelling
ELS reactions have been described following the fourth or
fifth dose of pediatric DTaP (131–136), and ELS has been
reported to VAERS almost as frequently following Td as fol-
lowing pediatric DTaP (136). ELS is not disabling, is not
often brought to medical attention, and resolves without com-
plication within 4–7 days (137). ELS is not considered a pre-
caution or contraindication for Tdap (138).
Interval Between Td and Tdap
ACIP has recommended a 10-year interval for routine ad-
ministration of Td and encourages an interval of at least 5
years between the Td and Tdap dose for adolescents (12,33).
Although administering Td more often than every 10 years
(5 years for some tetanus-prone wounds) is not necessary to
provide protection against tetanus or diphtheria, administer-
ing a dose of Tdap <5 years after Td could provide a health
benefit by protecting against pertussis. Prelicensure clinical
trials of ADACEL® excluded persons who had received doses
of a diphtheria or tetanus toxoid-containing vaccine during
the preceding 5 years (116).
The safety of administering a dose of Tdap at intervals <5
years after Td or pediatric DTP/DTaP has not been studied
in adults but was evaluated in Canadian children and adoles-
cents (139). The largest Canadian study was a nonrandomized,
open-label study of 7,001 students aged 7–19 years residing
in Prince Edward Island. This study assessed the rates of ad-
verse events after ADACEL® and compared reactogenicity of
ADACEL® administered at year intervals of 2–9 years (eight
cohorts) versus >10 years after the last tetanus and diphtheria
toxoid-containing vaccine (Td, or pediatric DTP or DTaP).
The 2-year interval was defined as >18 months to <30 months.
Vaccination history for type of pertussis vaccine(s) received
(pediatric DTP and DTaP) also was assessed. The number of
persons assigned to cohorts ranged from 464 in the 2-year
cohort to 925 in the 8-year cohort. Among the persons in the
2-year cohort, 214 (46%) received the last tetanus and diph-
theria toxoid-containing vaccine 18–23 months before
ADACEL®. Adverse event diary cards were returned for 85%
of study participants with a known interval; 90% of persons in
the 2-year interval cohort provided safety data (139).
Four SAEs were reported in the Prince Edward Island study;
none were vaccine-related. No Arthus reaction was reported.
Rates of reported severe local adverse reactions, fever, or any
pain were not increased in persons who received ADACEL®
at intervals <10 years. Rates of local reactions were not in-
creased among persons who received 5 doses of pediatric DTP,
with or without Td (intervals of 2–3 years or 8–9 years).
Two smaller Canadian postlicensure safety studies in ado-
lescents also showed acceptable safety when ADACEL® was
administered at intervals <5 years after tetanus and diphthe-
ria toxoid-containing vaccines (140,141). Taken together, these
three Canadian studies support the safety of using ADACEL®
after Td at intervals <5 years. The largest study suggests inter-
vals as short as approximately 2 years are acceptably safe (139).
Because rates of local and systemic reactions after Tdap in
adults were lower than or comparable to rates in adolescents
during U.S. prelicensure trials, the safety of using intervals as
short of approximately 2 years between Td and Tdap in adults
can be inferred from the Canadian studies (111).
Simultaneous and Nonsimultaneous Vaccination
with Tdap and Diphtheria-Containing MCV4
Tdap and tetravalent meningococcal conjugate vaccine
([MCV4] Menactra® manufactured by sanofi pasteur,
Swiftwater, Pennsylvania) contain diphtheria toxoid
(142,143). Each of these vaccines is licensed for use in adults,
but MCV4 is not indicated for active vaccination against diph-
theria (143). In MCV4, the diphtheria toxoid (approximately
48 µg) serves as the carrier protein that improves immune
responses to meningococcal antigens. Precise comparisons
cannot be made between the quantity of diphtheria toxoid in
the vaccines; however, the amount in a dose of MCV4 is esti-
mated to be comparable to the average quantity in a dose of
pediatric DTaP (144). No prelicensure studies were conducted
of simultaneous or sequential vaccination with Tdap and
MCV4. ACIP has considered the potential for adverse events
following simultaneous and nonsimultaneous vaccination with
Tdap and MCV4 (12). ACIP recommends simultaneous vac-
cination with Tdap and MCV4 for adolescents when both
vaccines are indicated, and any sequence if simultaneous ad-
ministration is not feasible (12,138). The same principles ap-
ply to adult patients for whom Tdap and MCV4 are indicated.
Neurologic and Systemic Events
Associated with Vaccines with Pertussis
Components or Tetanus Toxoid-
Containing Vaccines
Vaccines with Pertussis Components
Concerns about the possible role of vaccines with pertussis
components in causing neurologic reactions or exacerbating
underlying neurologic conditions in infants and children are
long-standing (16,145). ACIP recommendations to defer per-
tussis vaccines in infants with suspected or evolving neuro-
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logical disease, including seizures, have been based primarily
on the assumption that neurologic events after vaccination
(with whole cell preparations in particular) might complicate
the subsequent evaluation of infants’ neurologic status (1,145).
In 1991, the Institute of Medicine (IOM) concluded that
evidence favored acceptance of a causal relation between pe-
diatric DTP vaccine and acute encephalopathy; IOM has not
evaluated associations between acellular vaccines and neuro-
logic events for evidence of causality (128). During 1993–
2002, active surveillance in Canada failed to ascertain any
acute encephalopathy cases causally related to whole cell or
acellular pertussis vaccines among a population administered
6.5 million doses of pertussis-containing vaccines (146). In
children with a history of encephalopathy not attributable to
another identifiable cause occurring within 7 days after vac-
cination, subsequent doses of pediatric DTaP vaccines are
contraindicated (1).
ACIP recommends that children with progressive neuro-
logic conditions not be vaccinated with Tdap until the con-
dition stabilizes (1). However, progressive neurologic disorders
that are chronic and stable (e.g., dementia) are more com-
mon among adults, and the possibility that Tdap would com-
plicate subsequent neurologic evaluation is of less clinical
concern. As a result, chronic progressive neurologic condi-
tions that are stable in adults do not constitute a reason to
delay Tdap; this is in contrast to unstable or evolving neuro-
logic conditions (e.g., cerebrovascular events and acute
encephalopathic conditions).
Tetanus Toxoid-Containing Vaccines
ACIP considers Guillain-Barré syndrome <6 weeks after
receipt of a tetanus toxoid-containing vaccine a precaution
for subsequent tetanus toxoid-containing vaccines (138). IOM
concluded that evidence favored acceptance of a causal rela-
tion between tetanus toxoid-containing vaccines and Guillain-
Barré syndrome. This decision is based primarily on a single,
well-documented case report (128,147). A subsequent analy-
sis of active surveillance data in both adult and pediatric popu-
lations failed to demonstrate an association between receipt
of a tetanus toxoid-containing vaccine and onset of Guillain-
Barré syndrome within 6 weeks following vaccination (145).
A history of brachial neuritis is not considered by ACIP to be
a precaution or contraindication for administration of tetanus
toxoid-containing vaccines (138,149,150). IOM concluded that
evidence from case reports and uncontrolled studies involving
tetanus toxoid-containing vaccines did favor a causal relation
between tetanus toxoid-containing vaccines and brachial neuri-
tis (128); however, brachial neuritis is usually self-limited. Bra-
chial neuritis is considered to be a compensable event through
the Vaccine Injury Compensation Program (VICP).
Economic Considerations
for Adult Tdap Use
Economic Burden
The morbidity and societal cost of pertussis in adults is
substantial. A study that retrospectively assessed the economic
burden of pertussis in children and adults in Monroe County,
New York, during 1989–1994 indicated that, although eco-
nomic costs were not identified separately by age group, 14
adults incurred an average of 0.8 outpatient visits and 0.2
emergency department visits per case (151). The mean time
to full recovery was 74 days. A prospective study in Monroe
Country, New York, during 1995–1996 identified six adult
cases with an average societal cost of $181 per case (152); one
third was attributed to nonmedical costs. The mean time to
full recovery was 66 days (range: 3–383 days). A study of the
medical costs associated with hospitalization in four states
during 1996–1999 found a mean total cost of $5,310 in 17
adolescents and 44 adults (153). Outpatient costs and non-
medical costs were not considered in this study.
A study in Massachusetts retrospectively assessed medical
costs of confirmed pertussis in 936 adults during 1998–2000
and prospectively assessed nonmedical costs in 203 adults
during 2001–2003 (42). The mean medical and nonmedical
cost per case was $326 and $447, respectively, for a societal
cost of $773. Nonmedical costs constituted 58% of the total
cost in adults. If the cost of antimicrobials to treat contacts
and the cost of personal time were included, the societal cost
could be as high as $1,952 per adult case.
Cost-Benefit and Cost-Effectiveness Analyses
of Adult Tdap Vaccination
Results of two economic evaluations that examined adult
vaccination strategies for pertussis varied. A cost-benefit analy-
sis in 2004 indicated that adult pertussis vaccination would
be cost-saving (154). A cost-effectiveness analysis in 2005 in-
dicated that adult pertussis vaccination would not be cost-
effective (155). The strategies and assumptions used in the
two models had two major differences. The universal vacci-
nation strategy used in cost-benefit analysis was a one-time
adult booster administered to all adults aged >20 years; the
strategy used in the cost-effectiveness study was for decennial
boosters over the lifetime of adults. The incidence estimates
used in the two models also differed. In the cost-benefit study,
incidence ranged from 159 per 100,000 population for adults
aged 20–29 years to 448 for adults aged >40 years. In con-
trast, the cost-effectiveness study used a conservative incidence
estimate of 11 per 100,000 population based on enhanced
surveillance data from Massachusetts. Neither study made
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adjustments for a decrease in disease severity that might be
associated with increased incidence. Adult strategies might
have appeared cost-effective or cost-saving at high incidence
because the distribution of the severity of disease was assumed
to the same regardless of incidence.
To address these discrepancies, the adult vaccination strat-
egy was re-examined using the cost-effectiveness study model
(155,156). The updated analysis estimated the cost-
effectiveness of vaccinating adults aged 20–64 years with a
single Tdap booster and explored the impact of incidence and
severity of disease on cost-effectiveness. Costs, health out-
comes, and cost-effectiveness were analyzed for a U.S. cohort
of approximately 166 million adults aged 20–64 years over a
10-year period. The revised analysis assumed an incremental
vaccine cost of $20 on the basis of updated price estimates of
Td and Tdap in the private and public sectors, an incidence
of adult pertussis ranging from 10–500 per 100,000 popula-
tion, and vaccine delivery estimates ranging from 57%–66%
among adults on the basis of recently published estimates.
Without an adult vaccination program, the estimated num-
ber of adult pertussis cases over a 10-year period ranged from
146,000 at an incidence of 10 per 100,000 population to 7.1
million at an incidence of 500 per 100,000 population. A
one-time adult vaccination program would prevent approxi-
mately 44% of cases over a 10-year period. The number of
quality adjusted life years (QALYs) saved by a vaccination
program varied substantially depending on disease incidence.
At a rate of 10 per 100,000 population, a vaccination pro-
gram resulted in net loss of QALYs because of the disutility
associated with vaccine adverse events. As disease incidence
increased, the benefits of preventing pertussis far outweighed
the risks associated with vaccine adverse events. The number
of QALYs saved by the one-time adult strategy was approxi-
mately 104,000 (incidence: 500 per 100,000 population).
The programmatic cost of a one-time adult vaccination strat-
egy would be $2.1 billion. Overall, the net cost of the one-
time adult vaccination program ranged from $0.5 to $2 billion
depending on disease incidence. The cost per case prevented
ranged from $31,000 per case prevented at an incidence of
10 per 100,000 population to $160 per case prevented at an
incidence of 500 per 100,000 (Table 12). The cost per QALY
saved ranged from “dominated” (where “No vaccination” is
preferred) at 10 per 100,000 population to $5,000 per QALY
saved at 500 per 100,000 population. On the basis of a bench-
mark of $50,000 per QALY saved (157–159), an adult vacci-
nation program became cost-effective when the incidence
exceeded 120 per 100,000 population. When adjustments
were made for severity of illness at high disease incidence,
little impact was observed on the overall cost-effectiveness of
a vaccination program.
Similar results were obtained when program costs and ben-
efits were analyzed over the lifetime of the adult cohort for
the one-time and decennial booster strategies (156).
Implementation of Adult Tdap
Recommendations
Routine Adult Tdap Vaccination
The introduction of Tdap for routine use among adults
offers an opportunity to improve adult vaccine coverage and
to offer protection against pertussis, tetanus, and diphtheria.
Serologic and survey data indicate that U.S. adults are
undervaccinated against tetanus and diphtheria, and that rates
of coverage decline with increasing age (98,160). Maintain-
ing seroprotection against tetanus and diphtheria through ad-
herence to ACIP-recommended boosters is important for
adults of all ages. ACIP has recommended that adults receive
a booster dose of tetanus toxoid-containing vaccine every 10
years, or as indicated for wound care, to maintain protective
levels of tetanus antitoxin, and that adults with uncertain his-
tory of primary vaccination receive a 3-dose primary series (33).
Every visit of an adult to a health-care provider should be re-
garded as an opportunity to assess the patient’s vaccination sta-
tus and, if indicated, to provide protection against tetanus,
diphtheria, and pertussis. Nationwide survey data indicate that
although only 68% of family physicians and internists who see
adult patients for outpatient primary care routinely administer
Td for health maintenance when indicated, 81% would rec-
ommend Tdap for their adult patients (161).
Vaccination of Adults in Contact
with Infants
Vaccinating adults aged <65 years with Tdap who have or
who anticipate having close contact with an infant could de-
crease the morbidity and mortality of pertussis among in-
fants by preventing pertussis in the adult and thereby
TABLE 12. Cost-effectiveness of a one-time adult vaccination
strategy at varying incidence over a 10-year period
Cost per case Cost per quality
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preventing transmission to the infant. Administration of Tdap
to adult contacts at least 2 weeks before contact with an in-
fant is optimal. Near peak antibody responses to pertussis
vaccine antigens can be achieved with booster doses by 7 days
postvaccination, as demonstrated in a study in Canadian chil-
dren after receipt of DTaP-IPV booster (131).
The strategy of vaccinating contacts of persons at high risk
to reduce disease and therefore transmission is used with in-
fluenza. Influenza vaccine is recommended for household
contacts and out-of-home caregivers of children aged 0–59
months, particularly infants aged 0–6 months, the pediatric
group at greatest risk for influenza-associated complications
(162). A similar strategy for Tdap is likely to be acceptable to
physicians. In a 2005 national survey, 62% of obstetricians sur-
veyed reported that obstetricians and adult primary-care pro-
viders should administer Tdap to adults anticipating contact
with an infant, if recommended by ACIP and the American
College of Obstetricians and Gynecologists (ACOG) (163).
Protecting women with Tdap before pregnancy also could
reduce the number of mothers who acquire and transmit per-
tussis to their infant. ACOG states that preconceptional vac-
cination of women to prevent disease in the offspring, when
practical, is preferred to vaccination of pregnant women (164).
Because approximately half of all pregnancies in the United
States are unplanned, targeting women of child-bearing age
before they become pregnant for a dose of Tdap might be the
most effective strategy (165). Vaccinating susceptible women
of childbearing age with measles, mumps, and rubella vac-
cine also is recommended to protect the mother and to pre-
vent transmission to the fetus or young infant (166).
Implementing preconception vaccination in general medical
offices, gynecology outpatient care centers, and family-
planning clinics is essential to ensure the success of this pre-
ventive strategy.
If Tdap vaccine is not administered before pregnancy, im-
mediate postpartum vaccination of new mothers is an alter-
native. Rubella vaccination has been successfully administered
postpartum. In studies in New Hampshire and other sites,
approximately 65% of rubella-susceptible women who gave
birth received MMR postpartum (167,168). In a nationwide
survey, 78% of obstetricians reported that they would recom-
mend Tdap for women during the postpartum hospital stay
if it were recommended (163). Vaccination before discharge
from the hospital or birthing center, rather than at a follow-
up visit, has the advantage of decreasing the time when new
mothers could acquire and transmit pertussis to their new-
born. Other household members, including fathers, should
receive Tdap before the birth of the infant as recommended.
Mathematical modeling can provide useful information
about the potential effectiveness of a vaccination strategy tar-
geting contacts of infants. One model evaluating different
vaccine strategies in the United States suggested that vacci-
nating household contacts of newborns, in addition to rou-
tine adolescent Tdap vaccination, could prevent 76% of cases
in infants aged <3 months (169). A second model from Aus-
tralia estimated a 38% reduction in cases and deaths among
infants aged <12 months if both parents of the infant were
vaccinated before the infant was discharged from the hospital
(170).
Vaccination of Pregnant Women
ACIP has recommended Td routinely for pregnant women
who received the last tetanus toxoid-containing vaccine >10
years earlier to prevent maternal and neonatal tetanus (33,171).
Among women vaccinated against tetanus, passive transfer of
antitetanus antibodies across the placenta during pregnancy
protect their newborn from neonatal tetanus (101,172,173).
As with tetanus, antibodies to pertussis antigens are pas-
sively transferred during pregnancy (174,175); however, se-
rologic correlates of protection against pertussis are not known
(113). Whether passive transfer of maternal antibodies to per-
tussis antigens protects neonates against pertussis is not clear
(113,176); whether increased titers of passive antibody to per-
tussis vaccine antigens substantially interfere with response
to DTaP during infancy remains an important question (177–
179). All licensed Td and Tdap vaccines are categorized as
Pregnancy Category C†† agents by FDA. Pregnant women
were excluded from prelicensure trials, and animal reproduc-
tion studies have not been conducted for Td or Tdap
(111,180–183). Td and TT have been used extensively in
pregnant women, and no evidence indicates use of tetanus




This section has been reviewed by and is supported by the
Healthcare Infection Control Practices Advisory Committee
(HICPAC)
Nosocomial spread of pertussis has been documented in
various health-care settings, including hospitals and emergency
†† U.S. Food and Drug Administration Pregnancy Category C. Animal studies
have documented an adverse effect, and no adequate and well-controlled studies
in pregnant women have been conducted or no animal studies and no adequate
and well-controlled studies in pregnant women have been conducted.
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departments serving pediatric and adult patients (186–189),
out-patient clinics (CDC, unpublished data, 2005), nursing
homes (89), and long-term–care facilities (190–193). The source
case of pertussis has been reported as a patient (188,194–196),
HCP with hospital- or community-acquired pertussis
(192,197,198), or a visitor or family member (199–201).
Symptoms of early pertussis (catarrhal phase) are indistin-
guishable from other respiratory infections and conditions.
When pertussis is not considered early in the differential di-
agnosis of patients with compatible symptoms, HCP and
patients are exposed to pertussis, and inconsistent use of face
or nose and mouth protection during evaluation and delay in
isolating patients can occur (187,188,197,200,202). One
study described the diagnosis of pertussis being considered in
an HCP experiencing paroxysmal cough, posttussive emesis,
and spontaneous pneumothorax, but only after an infant pa-
tient was diagnosed with pertussis 1 month later and after
three other HCP had been infected (198). Pertussis among
HCP and patients can result in substantial morbidity
(187,188,197,200,202). Infants who have nosocomial per-
tussis are at substantial risk for severe and, rarely, fatal disease
(187,188,197,200,202).
Risk for Pertussis Among HCP
HCP are at risk for being exposed to pertussis in inpatient
and outpatient pediatric facilities (186–188,194–
200,203,204) and in adult health-care facilities and settings
including emergency departments (196,202,205–207). In a
survey of infection-control practitioners from pediatric hos-
pitals, 90% reported HCP exposures to pertussis over a 5-
year period; at 11% of the reporting institutions, a physician
contracted the disease (208). A retrospective study conducted
in a Massachusetts tertiary-care center with medical, surgical,
pediatric, and obstetrical services during October 2003–
September 2004 documented pertussis in 20 patients and three
HCP, and pertussis exposure in approximately 300 HCP
(209). One infected HCP exposed 191 other persons, includ-
ing co-workers and patients in a postanesthesia care unit.
Despite aggressive investigation and prophylaxis, a patient and
the HCP’s spouse were infected (209).
In a California university hospital with pediatric services,
25 patients exposed 27 HCP over a 5-year period (210). At a
North Carolina teaching hospital during 2002–2005, a total
of 21 pertussis patients exposed 72 unprotected HCP (DJ
Weber, Hospital Epidemiology and Occupational Health,
University of North Carolina Health Care System, personal
communication, 2006). A Philadelphia children’s hospital that
tracked exposures during September 2003–April 2005 iden-
tified seven patients who exposed 355 unprotected HCP
(211). The exposed HCP included 163 nurses, 106 physi-
cians, 42 radiology technicians, 29 respiratory therapists, and
15 others. Recent estimates suggest that up to nine HCP are
exposed on average for each case of pertussis with delayed
diagnosis (203).
Serologic studies among hospital staff suggest B. pertussis
infection among HCP is more frequent than suggested by the
attack rates of clinical disease (212,213). In one study, annual
rates of infection among a group of clerical HCP with mini-
mal patient contact ranged from 4%–43% depending on the
serologic marker used (4%–16% based on anti-PT IgG anti-
bodies) (208). The seroprevalence of pertussis agglutinating
antibodies among HCPs in one hospital outbreak correlated
with the degree of patient contact. Pediatric house staff and
ward nurses were 2–3 times more likely to have B. pertussis
agglutinating antibodies than nurses with administrative re-
sponsibilities, 82% and 71% versus 35%, respectively (197).
In another study, the annual incidence of B. pertussis infec-
tion among emergency department staff was approximately
three times higher than among resident physicians (3.6% ver-
sus 1.3%, respectively), on the basis of elevated anti-PT IgG
titers. Two of five HCP (40%) with elevated anti-PT IgG
titers had clinical signs of pertussis (213).
The risk for pertussis among HCP relative to the general
population was estimated in a Quebec study of adult and
adolescent pertussis. Among the 384 (58%) of 664 eligible
cases among adults aged >18 years (41), HCP accounted for
32 (8%) of the pertussis cases and 5% of the population. Per-
tussis among HCP was 1.7 times higher than among the gen-
eral population. Similar studies have not been conducted in
the United States.
Pertussis outbreaks are reported from chronic-care or nursing
home facilities and in residential-care institutions; these HCP
might be at increased risk for pertussis. However, the risk for
pertussis among HCP in these settings compared with the gen-
eral population has not been evaluated (190–193).
Management of Exposed Persons in Settings
with Nosocomial Pertussis
Investigation and control measures to prevent pertussis af-
ter unprotected exposure in health-care settings are labor in-
tensive, disruptive, and costly, particularly when the number
of exposed contacts is large (203). Such measures include iden-
tifying contacts among HCP and patients, providing
postexposure prophylaxis for asymptomatic close contacts, and
evaluating, treating, and placing symptomatic HCP on ad-
ministrative leave until they have received effective treatment.
Despite the effectiveness of control measures to prevent fur-
ther transmission of pertussis, one or more cycle of transmis-
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sion with exposures and secondary cases can occur before
pertussis is recognized. This might occur regardless of whether
the source case is a patient or HCP, the age of the source case,
or the setting (e.g., emergency department [203], postopera-
tive suite or surgical ward [209,214], nursery [198,215], in-
patient ward [187,194,216], or maternity ambulatory care
[202]). The number of reported outbreak-related secondary
cases ranges from none to approximately 80 per index case and
includes other HCP (205), adults (209), and pediatric patients
(203). Secondary cases among infants have resulted in prolonged
hospital stay, mechanical ventilation (198), or death (215).
The cost of controlling nosocomial pertussis is high, re-
gardless of the size of the outbreak. The impact of pertussis
on productivity can be substantial, even when no secondary
case of pertussis occurs. The hospital costs result from infec-
tion prevention and control/occupational health employee
time to identify and notify exposed patients and personnel,
to educate personnel in involved areas, and to communicate
with HCP and the public; from providing prophylactic anti-
microbial agents for exposed personnel; laboratory testing and
treating symptomatic contacts; placing symptomatic person-
nel on administrative leave; and lost time from work for illness.
Cost-Benefit of Vaccinating Health-Care
Personnel with Tdap
By vaccinating HCP with Tdap and reducing the number
of cases of pertussis among HCP, hospitals will reduce the
costs associated with resource-intensive hospital investigations
and control measures (e.g., case/contact tracking, postexposure
prophylaxis, and treatment of hospital acquired pertussis
cases). These costs can be substantial. In four recent hospital-
based pertussis outbreaks, the cost of controlling pertussis
ranged from $74,870–$174,327 per outbreak (203,207). In
a Massachusetts hospital providing pediatric, adult, and ob-
stetrical care, a prospective study found that the cost of man-
aging pertussis exposures over a 12-month period was
$84,000–$98,000 (209). Similarly, in a Philadelphia pediat-
ric hospital, the estimated cost of managing unprotected ex-
posures over a 20-month period was $42,900 (211).
Vaccinating HCP could be cost-beneficial for health-care fa-
cilities if vaccination reduces nosocomial infections and out-
breaks, decreases transmission, and prevents secondary cases.
These cost savings would be realized even with no change in
the guidelines for investigation and control measures.
A model to estimate the cost of vaccinating HCP and the
net return from preventing nosocomial pertussis was con-
structed using probabilistic methods and a hypothetical co-
hort of 1,000 HCP followed for 10 years. Data from the
literature were used to determine baseline assumptions. The
annual rate of pertussis infection among HCP was approxi-
mately 7% on the basis of reported serosurveys (212,213); of
these, 40% were assumed to be symptomatic (213). The ratio
of identified exposures per HCP case was estimated to be nine
(187,199,202,206), and the cost of infection-control mea-
sures per exposed person was estimated to be $231
(187,203,209). Employment turnover rates were estimated
to be 17% (217,218), mean vaccine effectiveness was 71%
over 10 years (28,155), vaccine coverage was 66% (160), the
rate of anaphylaxis following vaccination was 0.0001%
(42,219,220), and the costs of vaccine was $30 per dose
(155,221). For each year, the number of nosocomial pertussis
exposures requiring investigation and control interventions
was calculated for two scenarios: with or without a vaccina-
tion program for HCP having direct patient contact.
In the absence of vaccination, approximately 203 (range:
34–661) nosocomial exposures would occur per 1,000 HCP
annually. The vaccination program would prevent 93 (range:
13–310) annual nosocomial pertussis exposures per 1,000
HCP per year. Over a 10-year period, the cost of infection
control without vaccination would be $388,000; with a Tdap
vaccination program, the cost of infection control would be
$213,000. The Tdap vaccination program for a stable popu-
lation of 1,000 HCP population over the same period would
be $69,000. Introduction of a vaccination program would
result in an estimated median net savings of $95,000 and a
benefit-cost ratio of 2.38 (range: 0.4–10.9) (i.e., for every
dollar spent on the vaccination program, the hospital would
save $2.38 on control measures).
Implementing a Hospital Tdap Program
Infrastructure for screening, administering, and tracking
vaccinations exists at occupational health or infection pre-
vention and control departments in most hospitals and is ex-
pected to provide the infrastructure to implement Tdap
vaccination programs. New personnel can be screened and
vaccinated with Tdap when they begin employment. As Tdap
vaccination coverage in the general population increases, many
new HCP will have already received a dose of Tdap.
To achieve optimal Tdap coverage among personnel in
health-care settings, health-care facilities are encouraged to
use strategies that have enhanced HCP participation in other
hospital vaccination campaigns. Successful strategies for hos-
pital influenza vaccine campaigns have included strong pro-
active educational programs designed at appropriate
educational and language levels for the targeted HCP, vacci-
nation clinics in areas convenient to HCP, vaccination at
worksites, and provision of vaccine at no cost to the HCP
(222–224). Some health-care institutions might favor a tiered
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approach to Tdap vaccination, with priority given to HCP
who have contact with infants aged <12 months and other
vulnerable groups of patients.
Purchase and administration of Tdap for HCP is an added
financial and operational burden for health-care facilities. A
cost-benefit model suggests that the cost of a Tdap vaccina-
tion program for HCP is offset by reductions in investigation
and control measures for pertussis exposures from HCP, in
addition to the anticipated enhancement of HCP and patient
safety (203).
Pertussis Exposures Among HCP Previously
Vaccinated with Tdap
Health-care facilities could realize substantial cost-saving if
exposed HCP who are already vaccinated against pertussis
with Tdap were exempt from control interventions (225). The
guidelines for control of pertussis in health-care settings were
developed before pertussis vaccine (Tdap) was available for
adults (68,226). Studies are needed to evaluate the effective-
ness of Tdap to prevent pertussis in vaccinated HCP, the du-
ration of protection, and the effectiveness of Tdap in
preventing infected vaccinated HCP from transmitting B. per-
tussis to patients and other HCP. Until studies define the op-
timal management of exposed vaccinated HCP or a consensus
of experts is developed, health-care facilities should continue
postexposure prophylaxis for vaccinated HCP who have un-
protected exposure to pertussis.
Alternatively, each health-care facility can determine an
appropriate strategy for managing exposed vaccinated HCP
on the basis of available human and fiscal resources and
whether the patient population served is at risk for severe per-
tussis if transmission were to occur from an unrecognized case
in a vaccinated HCP. Some health-care facilities might have
infrastructure to provide daily monitoring of exposed vacci-
nated HCP for early symptoms of pertussis and for institut-
ing prompt assessment, treatment, and administrative leave if
early signs or symptoms of pertussis develop. Daily monitor-
ing of HCP 21–28 days before beginning each work shift has
been successful for vaccinated workers exposed to varicella
(227,228) and for monitoring the site of vaccinia (smallpox
vaccine) inoculation (229,230). Daily monitoring of pertus-
sis-exposed HCP who received Tdap might be a reasonable
strategy for postexposure management, because the incuba-
tion period of pertussis is up to 21 days and the minimal risk
for transmission before the onset of signs and symptoms of
pertussis. In considering this approach, hospitals should maxi-
mize efforts to prevent transmission of B. pertussis to infants
or other groups of vulnerable persons. Additional study is
needed to determine the effectiveness of this control strategy.
Recommendations
The following recommendations for the use of Tdap
(ADACEL®) are intended for adults aged 19–64 years who
have not already received a dose of Tdap. Tdap is licensed for
a single use only; prelicensure studies on the safety or efficacy
of subsequent doses were not conducted. After receipt of a
single dose of Tdap, subsequent doses of tetanus- and diph-
theria toxoid-containing vaccines should follow guidance from
previously published recommendations for the use of Td and
TT (33). Adults should receive a decennial booster with Td
beginning 10 years after receipt of Tdap (33). Recommenda-
tions for the use of Tdap (ADACEL® and BOOSTRIX®)
among adolescents are described elsewhere (12).
BOOSTRIX® is not licensed for use in adults.
1. Routine Tdap Vaccination
1-A. Recommendations for Use
1) Routine use: Adults aged 19–64 years should
receive a single dose of Tdap to replace a single
dose of Td for active booster vaccination against
tetanus, diphtheria, and pertussis if they received
their last dose of Td >10 years earlier. Replac-
ing 1 dose of Td with Tdap will reduce the
morbidity associated with pertussis in adults and
might reduce the risk for transmitting pertussis
to persons at increased risk for pertussis and its
complications.
2) Short interval between Td and Tdap: Intervals
<10 years since the last Td may be used to pro-
tect against pertussis. Particularly in settings
with increased risk for pertussis or its compli-
cations, the benefit of using a single dose of Tdap
at an interval <10 years to protect against per-
tussis generally outweighs the risk for local and
systemic reactions after vaccination. The safety
of an interval as short as approximately 2 years
between Td and Tdap is supported by a Cana-
dian study; shorter intervals may be used (see
Safety Considerations for Adult Vaccination
with Tdap).
For adults who require tetanus toxoid-contain-
ing vaccine as part of wound management, a
single dose of Tdap is preferred to Td if they
have not previously received Tdap (see Tetanus
Prophylaxis in Wound Management).
3) Prevention of pertussis among infants aged <12
months by vaccinating their adult contacts:
Adults who have or who anticipate having close
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contact with an infant aged <12 months (e.g.,
parents, grandparents aged <65 years, child-care
providers, and HCP) should receive a single dose
of Tdap at intervals <10 years since the last Td
to protect against pertussis if they have not pre-
viously received Tdap. Ideally, these adults
should receive Tdap at least 2 weeks before be-
ginning close contact with the infant. An inter-
val as short as 2 years from the last dose of Td is
suggested to reduce the risk for local and sys-
temic reactions after vaccination; shorter inter-
vals may be used.
Infants aged <12 months are at highest risk for
pertussis-related complications and hospitaliza-
tions compared with older age groups. Young
infants have the highest risk for death. Vacci-
nating adult contacts might reduce the risk for
transmitting pertussis to these infants (see In-
fant Pertussis and Transmission to Infants). In-
fants should be vaccinated on-time with
pediatric DTaP (1,231).
When possible, women should receive Tdap be-
fore becoming pregnant. Approximately half of
all pregnancies in the United States are un-
planned (165). Any woman of childbearing age
who might become pregnant is encouraged to
receive a single dose of Tdap if she has not pre-
viously received Tdap (see Vaccination During
Pregnancy).
Women, including those who are breastfeeding,
should receive a dose of Tdap in the immediate
postpartum period if they have not previously
received Tdap. The postpartum Tdap should
be administered before discharge from the hos-
pital or birthing center. If Tdap cannot be ad-
ministered before discharge, it should be
administered as soon as feasible.
4) Health-Care Personnel§§: HCP in hospitals or
ambulatory care settings¶¶ who have direct pa-
tient contact should receive a single dose of Tdap
as soon as feasible if they have not previously
received Tdap. Although Td booster doses are
routinely recommended at an interval of 10
years, an interval as short as 2 years from the
last dose of Td is recommended for the Tdap
dose among these HCP. These HCP include but
are not limited to physicians, other primary-
care providers, nurses, aides, respiratory thera-
pists, radiology technicians, students (e.g.,
medical, nursing, and other), dentists, social
workers, chaplains, volunteers, and dietary and
clerical workers.
Other HCP (i.e., not in hospitals or ambula-
tory care settings or without direct patient con-
tact) should receive a single dose of Tdap to
replace the next scheduled Td according to the
routine recommendation at an interval no
greater than 10 years since the last Td. They are
encouraged to receive the Tdap dose at an in-
terval as short as 2 years following the last Td.
Vaccinating HCP with Tdap will protect them
against pertussis and is expected to reduce trans-
mission to patients, other HCP, household
members, and persons in the community. Pri-
ority should be given to vaccination of HCP
who have direct contact with infants aged <12
months (see Prevention of Pertussis Among In-
fants Aged <12 Months by Vaccinating their
Adult Contacts).
Hospitals and ambulatory-care facilities should
provide Tdap for HCP and use approaches that
maximize vaccination rates (e.g., education
about the benefits of vaccination, convenient
access, and the provision of Tdap at no charge)
(see Implementing a Hospital Tdap Program).
Tdap is not licensed for multiple administra-
tions. After receipt of Tdap, HCP should re-
ceive Td or TT for booster immunization
against tetanus and diphtheria according to pre-
viously published guidelines (33).
Routine adult Tdap vaccination recommendations
are supported by evidence from randomized con-
trolled clinical trials, a nonrandomized open-label
trial, observational studies, and expert opinion
(Table 13).
1-B. Dosage and Administration
The dose of Tdap is 0.5 mL, administered intra-
muscularly (IM), preferably into the deltoid muscle.
§§ Recommendations for use of Tdap among HCP were reviewed and are
supported by the members of HICPAC.
¶¶ Hospitals, as defined by the Joint Commission on Accreditation of
Healthcare Organizations, do not include long-term–care facilities such as
nursing homes, skilled-nursing facilities, or rehabilitation and convalescent-
care facilities. Ambulatory-care settings include all outpatient and walk-in
facilities.
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1-C. Simultaneous Vaccination with Tdap and Other
Vaccines
If two or more vaccines are indicated, they should
be administered during the same visit (i.e., simul-
taneous vaccination). Each vaccine should be ad-
ministered using a separate syringe at a different
anatomic site. Certain experts recommend admin-
istering no more than two injections per muscle,
separated by at least 1 inch. Administering all indi-
cated vaccines during a single visit increases the like-
lihood that adults will receive recommended
vaccinations (138).
1-D.Preventing Adverse Events
The potential for administration errors involving
tetanus toxoid-containing vaccines and other vac-
cines is well documented (232–234). Pediatric
DTaP vaccine formulations should not be admin-
istered to adults. Attention to proper vaccination
technique, including use of an appropriate needle
length and standard routes of administration (i.e.,
IM for Tdap) might minimize the risk for adverse
events (138).
1-E. Record Keeping
Health-care providers who administer vaccines are
required to keep permanent vaccination records of
vaccines covered under the National Childhood
Vaccine Injury Compensation Act; ACIP has rec-
ommended that this practice include all vaccines
(138). Encouraging adults to maintain a personal
vaccination record is important to minimize admin-
istration of unnecessary vaccinations. Vaccine pro-
viders can record the type of the vaccine,
manufacturer, anatomic site, route, and date of ad-
ministration and name of the administering facil-
ity on the personal record.
2. Contraindications and Precautions
for Use of Tdap
2-A. Contraindications
• Tdap is contraindicated for persons with a history
of serious allergic reaction (i.e., anaphylaxis) to any
component of the vaccine. Because of the impor-
tance of tetanus vaccination, persons with a history
of anaphylaxis to components included in any Tdap
or Td vaccines should be referred to an allergist to
determine whether they have a specific allergy to
tetanus toxoid and can safely receive tetanus toxoid
(TT) vaccinations.
• Tdap is contraindicated for adults with a history of
encephalopathy (e.g., coma or prolonged seizures)
not attributable to an identifiable cause within 7
days of administration of a vaccine with pertussis
components. This contraindication is for the per-
tussis components, and these persons should receive
Td instead of Tdap.
2-B. Precautions and Reasons to Defer Tdap
A precaution is a condition in a vaccine recipient
that might increase the risk for a serious adverse
reaction (138). The following are precautions for
Tdap administration. In these situations, vaccine
providers should evaluate the risks for and benefits
of administering Tdap.
• Guillain-Barré syndrome <6 weeks after previous
dose of a tetanus toxoid-containing vaccine. If a
decision is made to continue vaccination with teta-
nus toxoid, Tdap is preferred to Td if otherwise
indicated.
Tdap vaccination should generally be deferred dur-
ing the following situations:
— Moderate or severe acute illness with or with-
out fever. Defer Tdap vaccination until the acute
illness resolves.
TABLE 13. Summary of evidence for routine adult tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis
(Tdap) vaccination
1: Efficacy against tetanus, diphtheria, and pertussis is
supported by immunogenicity results from randomized,
controlled clinical trials among adults; safety is supported
by results of randomized, controlled clinical trials among
adults.
2: The safety of an interval of approximately 2 years between
Td and Tdap is supported by a nonrandomized, open-
label clinical trial among children and adolescents.
3: Effectiveness of strategies to protect infants <12 months
of age by vaccinating their adult contacts has not been
studied and is based on expert opinion and data on the
frequency of adult household members identified as the
source of pertussis for infants.
4: Effectiveness of strategies to protect health-care personnel
and patients and to reduce the burden of pertussis in
health-care settings by vaccinating health-care personnel
has not been studied and is based on expert opinion and
experience in outbreak control.
24 MMWR December 15, 2006
— Unstable neurologic condition (e.g., cerebrovas-
cular events and acute encephalopathic condi-
tions) (see Safety Considerations for Adult
Vaccination with Tdap for a discussion of neu-
rological conditions).***
— History of an Arthus reaction following a pre-
vious dose of a tetanus toxoid-containing and/
or diphtheria toxoid-containing vaccine, includ-
ing MCV4 (see Safety Considerations for Adult
Vaccination with Tdap for description of Arthus
reaction). Vaccine providers should review the
patient’s medical history to verify the diagnosis
of Arthus reaction and can consult with an al-
lergist or immunologist. If an Arthus reaction
was likely, vaccine providers should consider de-
ferring Tdap vaccination until at least 10 years
have elapsed since the last tetanus toxoid-con-
taining and/or diphtheria toxoid-containing
vaccine was received. If the Arthus reaction was
associated with a vaccine that contained diph-
theria toxoid without tetanus toxoid (e.g.,
MCV4), deferring Tdap or Td might leave the
adult inadequately protected against tetanus. In
this situation, if the last tetanus toxoid-contain-
ing vaccine was administered >10 years earlier,
vaccine providers can obtain a serum tetanus
antitoxin level to evaluate the need for tetanus
vaccination (tetanus antitoxin levels >0.1 IU/
mL are considered protective) or administer TT.
2-C. Not Contraindications or Precautions for Tdap
The following conditions are not contraindications
or precautions for Tdap, and adults with these con-
ditions may receive a dose of Tdap if otherwise in-
dicated. The conditions in italics are precautions
for pediatric DTP/DTaP but are not
contraindications or precautions for Tdap vaccina-
tion in adults (1).
• Temperature >105°F (>40.5°C) within 48 hours
after pediatric DTP/DTaP not attributable to another
cause;
• Collapse or shock-like state (hypotonic hyporesponsive
episode) within 48 hours after pediatric DTP/DTaP;
• Persistent crying lasting >3 hours, occurring within
48 hours after pediatric DTP/DTaP;
• Convulsions with or without fever, occurring within
3 days after pediatric DTP/DTaP;
• Stable neurologic disorder, including well-con-
trolled seizures, a history of seizure disorder that
has resolved, and cerebral palsy (See section, Safety
Considerations for Adult Vaccination with Tdap);
• Brachial neuritis;
• Immunosuppression, including persons with hu-
man immunodeficiency virus (HIV). The immu-
nogenicity of Tdap in persons with
immunosuppression has not been studied and could
be suboptimal;
• Breastfeeding;
• Intercurrent minor illness;
• Use of antimicrobials;
• History of an extensive limb swelling reaction fol-
lowing pediatric DTP/DTaP or Td that was not an
Arthus hypersensitivity reaction (see Safety Con-
siderations for Adult Vaccination with Td section
for descriptions of ELS and Arthus reactions).
3. Special Situations for Tdap Use
3-A. Pertussis Outbreaks and Other Settings with In-
creased Risk for Pertussis or its Complications
During periods of increased community pertussis
activity or during pertussis outbreaks, vaccine pro-
viders might consider administering Tdap to adults
at an interval <10 years since the last Td or TT if
Tdap was not previously received (see Spacing and
Sequencing of Vaccines Containing Tetanus Tox-
oid, Diphtheria Toxoid, and Pertussis Antigens).
Postexposure chemoprophylaxis and other pertus-
sis control guidelines, including guidelines for HCP,
are described elsewhere (see Management of Ex-
posed Persons in Settings with Nosocomial Pertus-
sis) (168,226,235). The benefit of using a short
interval also might be increased for adults with co-
morbid medical conditions (see Clinical Features
and Morbidity Among Adults with Pertussis).
3-B. History of Pertussis
Adults who have a history of pertussis generally
should receive Tdap according to the routine rec-
ommendation. This practice is preferred because the
duration of protection induced by pertussis is un-
known (waning might begin as early as 7 years after
*** For adolescents, any progressive neurologic disorder (including progressive
encephalopathy) is considered a precaution for receipt of Tdap. For adults,
progressive neurologic disorders are considered precautions only if the
condition is unstable (CDC. Preventing tetanus, diphtheria, and pertussis
among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and
acellular pertussis vaccines: recommendations of the Advisory Committee
on Immunization Practices [ACIP]. MMWR 2006;55[No. RR-3]).
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infection [7]) and because the diagnosis of pertus-
sis can be difficult to confirm, particularly with tests
other than culture for B. pertussis. Administering
pertussis vaccine to persons with a history of per-
tussis presents no theoretical safety concern.
3-C. Tetanus Prophylaxis in Wound Management
ACIP has recommended administering tetanus tox-
oid-containing vaccine and tetanus immune globu-
lin (TIG) as part of standard wound management
to prevent tetanus (Table 14) (33). Tdap is preferred
to Td for adults vaccinated >5 years earlier who re-
quire a tetanus toxoid-containing vaccine as part of
wound management and who have not previously
received Tdap. For adults previously vaccinated with
Tdap, Td should be used if a tetanus toxoid-con-
taining vaccine is indicated for wound care. Adults
who have completed the 3-dose primary tetanus
vaccination series and have received a tetanus tox-
oid-containing vaccine <5 years earlier are protected
against tetanus and do not require a tetanus tox-
oid-containing vaccine as part of wound manage-
ment.
An attempt must be made to determine whether a
patient has completed the 3-dose primary tetanus
vaccination series. Persons with unknown or un-
certain previous tetanus vaccination histories should
be considered to have had no previous tetanus tox-
oid-containing vaccine. Persons who have not com-
pleted the primary series might require tetanus
toxoid and passive vaccination with TIG at the time
of wound management (Table 14). When both TIG
and a tetanus toxoid-containing vaccine are indi-
cated, each product should be administered using a
separate syringe at different anatomic sites.
Adults with a history of Arthus reaction following
a previous dose of a tetanus toxoid-containing vac-
cine should not receive a tetanus toxoid-containing
vaccine until >10 years after the most recent dose,
even if they have a wound that is neither clean nor
minor. If the Arthus reaction was associated with a
vaccine that contained diphtheria toxoid without
tetanus toxoid (e.g., MCV4), deferring Tdap or Td
might leave the adult inadequately protected against
tetanus, and TT should be administered (see pre-
cautions for management options). In all circum-
stances, the decision to administer TIG is based on
the primary vaccination history for tetanus
(Table 14).
3-D. Adults with History of Incomplete or Unknown
Tetanus, Diphtheria, or Pertussis Vaccination
Adults who have never been vaccinated against teta-
nus, diphtheria, or pertussis (no dose of pediatric
DTP/DTaP/DT or Td) should receive a series of
three vaccinations containing tetanus and diphthe-
ria toxoids. The preferred schedule is a single dose
of Tdap, followed by a dose of Td >4 weeks after
Tdap and another dose of Td 6–12 months later
(171). However, Tdap can substitute for any one of
the doses of Td in the 3-dose primary series. Alter-
natively, in situations in which the adult probably
received vaccination against tetanus and diphtheria
but cannot produce a record, vaccine providers may
consider serologic testing for antibodies to tetanus
and diphtheria toxin to avoid unnecessary vaccina-
tion. If tetanus and diphtheria antitoxin levels are
each >0.1 IU/mL, previous vaccination with teta-
nus and diphtheria toxoid vaccine is presumed, and
a single dose of Tdap is indicated.
Adults who received other incomplete vaccination
series against tetanus and diphtheria should be vac-
cinated with Tdap and/or Td to complete a 3-dose
primary series of tetanus and diphtheria toxoid-con-
taining vaccines. A single dose of Tdap can be used
in the series.
TABLE 14. Guide to tetanus prophylaxis in routine wound management among adults aged 19–64 years
Characteristic Clean, minor wound All other wounds*
History of adsorbed
tetanus toxoid (doses) Tdap or Td† TIG Tdap or Td† TIG
Unknown or <3 Yes No Yes Yes
>3 No§ No No¶ No
* Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles,
crushing, burns, and frostbite.
†Tdap is preferred to Td for adults who have never received Tdap.  Td is preferred to TT for adults who received Tdap previously or when Tdap is not
available. If TT and TIG are both used, Tetanus Toxoid Adsorbed rather than tetanus toxoid for booster use only (fluid vaccine) should be used.
§Yes, if >10 years since the last tetanus toxoid-containing vaccine dose.
¶ Yes, if >5 years since the last tetanus toxoid-containing vaccine dose.
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3-E. Nonsimultaneous Vaccination with Tdap and
Other Vaccines, Including MCV4
Inactivated vaccines may be administered at any
time before or after a different inactivated or live
vaccine, unless a contraindication exists (138). Si-
multaneous administration of Tdap (or Td) and
MCV4 (which all contain diphtheria toxoid) dur-
ing the same visit is preferred when both Tdap (or
Td) and MCV4 vaccines are indicated (12). If si-
multaneous vaccination is not feasible (e.g., a vac-
cine is not available), MCV4 and Tdap (or Td) can
be administered using any sequence. It is possible
that persons who recently received one diphtheria
toxoid-containing vaccine might have increased
rates for adverse reactions after a subsequent diph-
theria-containing vaccine when diphtheria toxoid
antibody titers remain elevated from the previous
vaccination (see Safety Considerations for Adult
Vaccination with Tdap).
3-F. Inadvertent Administration of Tdap
(BOOSTRIX®) or Pediatric DTaP
Of two licensed Tdap products, only ADACEL®
is licensed and recommended for use in adults.
BOOSTRIX® is licensed for persons aged 10–18
years and should not be administered to persons
aged >19 years. Pediatric DTaP is not indicated for
persons aged >7 years. To help prevent inadvertent
administration of BOOSTRIX® or pediatric DTaP
when ADACEL® is indicated, vaccine providers
should review product labels before administering
these vaccines; the packaging might appear similar.
If BOOSTRIX® or pediatric DTaP is administered
to an adult aged >19 years, this dose should count
as the Tdap dose and the patient should not receive
an additional dose of Tdap (ADACEL®). The pa-
tient should be informed of any inadvertent vac-
cine administration.
Both Tdap products are licensed for active booster
immunization as a single dose; neither are licensed
for multiple administrations. After receipt of Tdap,
persons should receive Td for booster immuniza-
tion against tetanus and diphtheria, according to
previously published guidelines (33). If a dose of
Tdap is administered to a person who has previ-
ously received Tdap, this dose should count as the
next dose of tetanus toxoid-containing vaccine.
3-G. Vaccination during Pregnancy
Recommendations for pregnant women will be pub-
lished separately (236). As with other inactivated
vaccines and toxoids, pregnancy is not considered
a contraindication for Tdap vaccination (138). Preg-
nant women who received the last tetanus toxoid-
containing vaccine during the preceding 10 years
and who have not previously received Tdap gener-
ally should receive Tdap after delivery. In situations
in which booster protection against tetanus and
diphtheria is indicated in pregnant women, the
ACIP generally recommends Td. Providers should
refer to recommendations for pregnant women for
further information (138,236).
Because of lack of data on the use of Tdap in preg-
nant women, sanofi pasteur has established a preg-
nancy registry. Health-care providers are encouraged
to report Tdap (ADACEL®) vaccination during
pregnancy, regardless of trimester, to sanofi pasteur
(telephone: 800-822-2463).
3-H. Adults Aged >65 Years
Tdap is not licensed for use among adults aged >65
years. The safety and immunogenicity of Tdap
among adults aged >65 years were not studied dur-
ing U.S. pre-licensure trials. Adults aged >65 years
should receive a dose of Td every 10 years for pro-
tection against tetanus and diphtheria and as indi-
cated for wound management (33).
Research on the immunogenicity and safety of Tdap
among adults aged >65 years is needed. Recommen-
dations for use of Tdap in adults aged >65 years
will be updated as new data become available.
Reporting of Adverse Events
After Vaccination
As with any newly licensed vaccine, surveillance for rare
adverse events associated with administration of Tdap is im-
portant for assessing its safety in large-scale use. The National
Childhood Vaccine Injury Act of 1986 requires health-care
providers to report specific adverse events that follow teta-
nus, diphtheria, or pertussis vaccination (http://vaers.hhs.gov/
reportable.htm). All clinically significant adverse events should
be reported to VAERS, even if causal relation to vaccination
is not apparent. VAERS reporting forms and information are
available electronically at http://www.vaers.org or by telephone
(800-822-7967). Web-based reporting is available and pro-
viders are encouraged to report electronically at https://
secure.vaers.org/VaersDataEntryintro.htm to promote better
timeliness and quality of safety data.
Vol. 55 / RR-17 Recommendations and Reports 27
Vaccine Injury Compensation
VICP, established by the National Childhood Vaccine In-
jury Act of 1986, is a system under which compensation can
be paid on behalf of a person thought to have been injured or
to have died as a result of receiving a vaccine covered by the
program. The program is intended as an alternative to civil
litigation under the traditional tort system because negligence
need not be proven.
The Act establishes 1) a Vaccine Injury Compensation Table
that lists the vaccines covered by the program; 2) the injuries,
disabilities, and conditions (including death) for which com-
pensation can be paid without proof of causation; and 3) the
period after vaccination during which the first symptom or
substantial aggravation of the injury must appear. Persons can
be compensated for an injury listed in the established table or
one that can be demonstrated to result from administration
of a listed vaccine. All tetanus toxoid-containing vaccines and
vaccines with pertussis components (e.g., Tdap) are covered
under the act. Additional information about the program is
available at http://www.hrsa.gov/osp/vicp or by telephone
(800-338-2382).
Areas of Future Research Related
to Tdap and Adults
With recent licensure and introduction of Tdap for adults,
close monitoring of pertussis trends and vaccine safety will be
priorities for public health organizations and health-care pro-
viders. Active surveillance sites in Massachusetts and Minne-
sota, supported by CDC, are being established to provide
additional data on the burden of pertussis among adults and
the impact of adult Tdap vaccination policy. Postlicensure
studies and surveillance activities are planned or underway to
evaluate changes in the incidence of pertussis, the uptake of
Tdap, and the duration and effectiveness of Tdap vaccine. Fur-
ther research is needed to establish the safety and immunogencity
of Tdap among adults aged >65 years and among pregnant
women and their infants; to evaluate the effectiveness of defer-
ring prophylaxis among recently vaccinated health-care per-
sonnel exposed to pertussis; to assess the safety, effectiveness
and duration of protection of repeated Tdap doses; to develop
improved diagnostic tests for pertussis; and to evaluate and
define immunologic correlates of protection for pertussis.
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The following recommendations for a single dose of Tdap
(ADACEL®) apply to adults aged 19–64 years who have not
yet received Tdap. Adults should receive a decennial booster
with Td beginning 10 years after receipt of Tdap (33).
• Routine: Adults should receive a single dose of Tdap to
replace a single dose of Td for booster immunization
against tetanus, diphtheria, and pertussis if they received
their most recent tetanus toxoid-containing vaccine (e.g.,
Td) >10 years earlier.
• Short intervals between Td and Tdap: Tdap can be
administered at an interval <10 years since receipt of the
last tetanus toxoid-containing vaccine to protect against
pertussis. The safety of intervals as short as approximately
2 years between administration of Td and Tdap is sup-
ported by a Canadian study of children and adolescents.
The dose of Tdap replaces the next scheduled Td booster.
• Prevention of pertussis among infants aged <12
months by vaccinating adult contacts: Adults who have
or who anticipate having close contact with an infant aged
<12 months (e.g., parents, grandparents, child-care pro-
viders, or health-care providers) should receive a single
dose of Tdap. An interval as short as 2 years since the
most recent tetanus toxoid-containing vaccine is suggested;
shorter intervals can be used. Ideally, Tdap should be ad-
ministered at least 2 weeks before beginning close contact
with the infant. Women should receive a dose of Tdap in
the immediate postpartum period if they have not previ-
ously received Tdap. Any woman who might become preg-
nant is encouraged to receive a single dose of Tdap.
• Vaccination of health-care personnel (HCP): HCP in
hospitals and ambulatory care settings who have direct
patient contact should receive a single dose of Tdap as
soon as feasible if they have not previously received Tdap.
An interval as short as 2 years because the last dose of Td
is recommended. Other HCP should receive a single dose
of Tdap according to the routine recommendation; they
are encouraged also to receive Tdap at an interval as short
as 2 years. Priority should be given to vaccination of HCP
who have direct contact with infants aged <12 months.
Hospitals and ambulatory-care facilities should provide
Tdap for HCP and use approaches that maximize vacci-
nation rates.
• Simultaneous administration: Tdap should be admin-
istered with other vaccines that are indicated during the
same visit when feasible. Each vaccine should be admin-
istered using a separate syringe at different anatomic sites.
APPENDIX A. Summary of Recommendations for Tetanus Toxoid, Reduced
Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) Use Among Adults
Special Situations
• History of pertussis: Adults with a history of pertussis
generally should receive Tdap according to the routine
recommendations.
• Tetanus prophylaxis in wound management: Adults
aged 19–64 years who require a tetanus toxoid-contain-
ing vaccine as part of wound management should receive
Tdap instead of Td if they have not previously received
Tdap. If Tdap is not available or was administered previ-
ously, Td should be administered.
• Incomplete or unknown vaccination history: Adults
who have never received tetanus and diphtheria toxoid-
containing vaccine should receive a series of three vacci-
nations. The preferred schedule is a single dose of Tdap
followed by Td >4 weeks later and a second dose of Td
6–12 months later. Tdap can substitute for Td for any
one of the 3 doses in the series.
• Pregnancy: Pregnancy is not a contraindication for Tdap
or Td vaccination. Guidance on the use of Tdap during
pregnancy is published separately (236).
• Adults aged >65 years: Tdap is not licensed for use
among adults aged >65 years.  The safety and immuno-
genicity of Tdap among adults aged >65 years was not
studied during U.S. prelicensure trials.
Contraindications to Tdap
• History of serious allergic reaction (i.e., anaphylaxis) to
vaccine components.
• History of encephalopathy (e.g., coma, prolonged sei-
zures) not attributable to an identifiable cause within 7
days of administration of a pertussis vaccine.
Precautions and reasons to defer Tdap:
• Guillain-Barré syndrome <6 weeks after a previous dose
of a tetanus toxoid-containing vaccine;
• Moderate to severe acute illness;
• Unstable neurological condition; and
• History of Arthus hypersensitivity reaction to a tetanus
toxoid-containing vaccine administered <10 years previ-
ously.
Reporting Adverse Events After Vaccination:
All clinically significant adverse events should be reported
to VAERS, even if a causal relation to vaccination is uncer-
tain. VAERS reporting forms and information are available
electronically at http://www.vaers.hhs.gov or by telephone
(800) 822-7967. Providers are encouraged to report electroni-
cally at https://secure.vaers.org/VaersDataEntryintro.htm.
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APPENDIX B. CDC and Council of State and Territorial
Epidemiologists (CSTE) Pertussis Case Definition*
Clinical Case Definition
• a cough illness lasting at least 2 weeks with one of the following: paroxysms of coughing, inspiratory
“whoop,” or posttussive vomiting, and without other apparent cause (as reported by a health-care profes-
sional)
Laboratory Criteria for Diagnosis
• isolation of Bordetella pertussis from a clinical specimen, or
• positive polymerase chain reaction (PCR) assay for B. pertussis
Case Classification
Confirmed
• an acute cough illness of any duration associated with B. pertussis isolation, or
• a case that meets the clinical case definition and is confirmed by PCR, or
• a case that meets the clinical definition and is epidemiologically linked directly to a case confirmed by
either culture or PCR
Probable
• a case that meets the clinical case definition, is not laboratory confirmed by culture or PCR, and is not
epidemiologically linked directly to a laboratory-confirmed case.
Sources: Guidelines for the control of pertussis outbreaks. Atlanta, GA: US Department of Health and Human Services, CDC. Available at
http://www.cdc.gov/nip/publications/pertussis/guide.htm. Council of State and Territorial Epidemiologists. CSTE position statement, 1997-
ID-9: Public health surveillance control and prevention of pertussis. Available at http://www.cste.org/ps/1997/1997-id-09.htm.
* Both probable and confirmed cases should be reported to the National Notifiable Diseases Surveillance System (http://www.cdc.gov/epo/
dphsi/nndsshis.htm).
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ACIP Advisory Committee on
Immunization Practices
ACOG American College of Obstetricians
and Gynecologists
ap acellular pertussis vaccine (without
tetanus and diphtheria toxoids)
B. bronchiseptica Bordetella bronchiseptica
B. holmseii Bordetella holmseii
B. parapertussis Bordetella parapertussis
B. pertussis Bordetella pertussis
C. diphtheriae Corynebacterium diphtheriae
C. tetani Clostridium tetani
C. ulcerans Corynebacterium ulcerans
CI confidence interval
CSTE Council of State and Territorial
Epidemiologists
DFA direct fluorescent antibody
DT pediatric diphtheria and tetanus
toxoids vaccine
DTaP pediatric diphtheria and tetanus
toxoids and acellular pertussis vaccine
DTP pediatric diphtheria and tetanus
toxoids and whole cell pertussis
vaccine
EU ELISA units
ELISA enzyme-linked immunoabsorbant assay
ELS extensive limb swelling




GMC geometric mean antibody
concentration




HIV human immunodeficiency virus
HICPAC Healthcare Infection Control Practices
Advisory Committee
IM intramuscularly
IOM Institute of Medicine
IU international units
Lf limit of flocculation unit
MCV4 tetravalent meningococcal conjugate
vaccine








NHANES National Health and Nutritional
Examination Survey
NNDSS National Notifiable Diseases
Surveillance System
PCR polymerase chain reaction
2-PE 2-phenoxyethanol
PRN Pertactin
PPD tuberculin purified protein derivative
PT pertussis toxin
QALY quality adjusted life year
SAE serious adverse event
sp sanofi Pasteur
SPSS Supplemental Pertussis Surveillance
System
Tdap adult tetanus toxoid, reduced diphtheria
toxoid and acellular pertussis vaccine
Td adult tetanus and diphtheria toxoids
vaccine
TIG tetanus immune globulin
TIV trivalent inactivated influenza vaccine
TT tetanus toxoid vaccine
VAERS Vaccine Adverse Event Reporting System
VICP Vaccine Injury Compensation Program
VRBPAC Vaccines and Related Biological
Products Advisory Committee
µg micrograms
APPENDIX C. Abbreviations Used in This Report
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To receive continuing education credit, please answer all of the following questions.
1. What age group is at the highest risk for pertussis-related
complications?
A. Infants aged <12 months.
B. Adolescents aged 11–18 years.
C. Adults aged 19–64 years.
D. Adults aged >65 years.
E. All age groups are at equal risk for complications of pertussis.
2. What proportion of reported cases of pertussis in the United States













4. Which of the following is a true statement about ADACEL®, the
acellular pertussis vaccine licensed for use among adults in the United
States?
A. The vaccine contains only one pertussis antigen.
B. The vaccine contains thimerosal as a preservative.
C. The vaccine was approved for use on the basis of the demonstration of
clinical efficacy against pertussis.
D. The vaccine is approved for a single dose.
E. The vaccine should be administered by the subcutaneous route.
5. Which of the following groups of persons aged 19-64 years is
recommended to receive Tdap?
A. Adults who require tetanus toxoid as part of wound management.
B. Health-care personnel.
C. Women of childbearing age.
D. Persons who have close contact with an infant aged <12 months.
E. All the above groups are recommended to receive Tdap.
6. What is the most common adverse reaction reported among adults
who receive acellular pertussis vaccine?
A. Pain at the vaccination site.
B. Headache.
C. Generalized rash.
D. Fever of >100°F (>38°C).
E. Anorexia.
7. What is the recommendation for use of Tdap among adults who have
never been vaccinated against tetanus, diphtheria, or pertussis?
A. Three doses of Tdap.
B. Two doses of Tdap followed by 1 dose of adult tetanus-diphtheria
toxoid (Td).
C. Two doses of Tdap followed by 2 doses of Td.
D. One dose of Tdap followed by 2 doses of Td.
E. Tdap vaccine should not be administered to adults who did not receive
pertussis vaccine as a child.
8. What is the minimum interval after a dose of Td that a dose of Tdap
can be administered?





9. What vaccine may be administered at the same visit as acellular
pertussis vaccine?
A. Meningococcal conjugate vaccine.
B. Hepatitis B vaccine.
C. Measles-mumps-rubella vaccine.
D. Varicella vaccine.
E. All the above vaccines may be administered at the same visit as acellular
pertussis vaccine.
10. Which of the following is a contraindication to the administration of
acellular pertussis vaccine to an adult?
A. Breastfeeding.
B. A history of a severe (anaphylactic) allergic reaction to a component of
the vaccine.
C. A history of pertussis disease as a child.
D. Immunosuppression resulting from infection with human
immunodeficiency virus.
E. All the above are contraindications to the administration of acellular
pertussis vaccine to an adult.






12. I plan to use these recommendations as the basis for …(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































13. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.







15. After reading this report, I am confident I can describe the







16. After reading this report, I am confident I can list Advisory Committee







17. After reading this report, I am confident I can identify













19. The instructional strategies used in this report (text, appendices,
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Correct answers for questions 1–10. 1. A; 2. B; 3. E; 4. D; 5. E; 6. A;
7. D; 8. A; 9. E; 10. B.


















24. The availability of continuing education credit influenced my decision












26. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
27. How did you learn about the continuing education activity?
A. Internet.
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